



MMWRTM


Morbidity and Mortality Weekly Report

Recommendations and Reports

June 22, 2007 / Vol. 56 / No. RR-4

Prevention of Varicella

Recommendations of the Advisory Committee on Immunization Practices (ACIP)



INSIDE: Continuing Education Examination

FDA Approval of an Extended Period for Administering VariZIG for Postexposure Prophylaxis of Varicella

VariZIG (Cangene Corporation, Winnipeg, Canada) is the only varicella zoster immune globulin preparation available in the United States for postexposure prophylaxis of varicella in persons at high risk for severe disease who lack evidence of immunity to varicella and are ineligible for varicella vaccine. VariZIG is available in the United States through an investigational new drug (IND) application expanded access protocol (1). VariZIG is a purified immune globulin preparation made from human plasma containing high levels of anti-varicella zoster virus antibodies (immunoglobulin G). In May 2011, the Food and Drug Administration (FDA) approved an extended period for administering VariZIG. The period after exposure to varicella zoster virus during which a patient may receive VariZIG, which had been 96 hours (4 days), is now 10 days (1). VariZIG should be administered as soon as possible after exposure (1).

Limited data suggest that the incidence of varicella is comparable among persons who receive varicella zoster immune globulin within 4 days of exposure and those who receive it more than 4 days (up to 10 days) after exposure and attenuation of disease might be achieved with administration of varicella zoster immune globulin up to 10 days after exposure (2–5). One study indicated an increase in varicella incidence with increasing time between exposure and administration of the immune globulin, but disease was attenuated in all cases (6).

VariZIG can be obtained by health-care providers from the sole-authorized U.S. distributor, FFF Enterprises (Temecula, California), by calling 800-843-7477 at any time or by contacting the distributor online at <http://www.fffenterprises.com>. As with any product used under an IND protocol, patients must give informed consent before receiving the product.

Advisory Committee on Immunization Practices (ACIP) recommendations regarding indications for the use of VariZIG remain unchanged (7,8). Patients without evidence of immunity to varicella (i.e., without a health-care provider diagnosis or verification of a history of varicella or herpes zoster, documentation of vaccination, or laboratory evidence of immunity or confirmation of disease) who are at high risk for severe disease and complications, who have been exposed to varicella or herpes zoster, and are ineligible for varicella vaccine, are eligible to receive VariZIG (7). Patient groups recommended by ACIP to receive VariZIG include the following:

- Immunocompromised patients.
- Neonates whose mothers have signs and symptoms of varicella around the time of delivery (i.e., 5 days before to 2 days after).
- Premature infants born at ≥ 28 weeks of gestation who are exposed during the neonatal period and whose mothers do not have evidence of immunity.
- Premature infants born at < 28 weeks of gestation or who weigh $\leq 1,000$ g at birth and were exposed during the neonatal period, regardless of their mothers' evidence of immunity status.
- Pregnant women.

VariZIG should be administered intramuscularly as directed by the manufacturer. Additional information on the process for obtaining VariZIG under the IND protocol, use of antiviral therapy if varicella occurs after administration of VariZIG, and the interval between administration of VariZIG and varicella vaccine once the patient becomes eligible is available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a5.htm> (8).

References

1. Food and Drug Administration. Varicella zoster immune globulin (VZIG) anticipated short supply and alternate product availability under an investigational new drug application expanded access protocol. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2006. Available at <http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm176029.htm>. Accessed March 28, 2012.
2. Evans EB, Pollock TM, Craddock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. *Lancet* 1980;315:354–6.
3. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. *Rev Med Microbiol* 1993;4:222–30.
4. Enders G, Miller E. Varicella and herpes zoster in pregnancy and the newborn. In: Arvin A, Gershon A, eds. *Varicella-zoster virus: virology and clinical management*. Cambridge, UK: Cambridge University Press; 2000.
5. Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. *J Clin Pharmacol* 2002;42:267–74.
6. Winsnes R. Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients. *Acta Paediatr Scand* 1978;67:77–82.
7. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2007;56(No. RR-4).
8. CDC. A new product (VariZIG™) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. *MMWR* 2006;55:209–10.

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Title]. *MMWR* 2007;56(No. RR-#):[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH
Director

Tanja Popovic, MD, PhD
Chief Science Officer

James W. Stephens, PhD
(Acting) Associate Director for Science

Steven L. Solomon, MD
Director, Coordinating Center for Health Information and Service

Jay M. Bernhardt, PhD, MPH
Director, National Center for Health Marketing

B. Kathleen Skipper, MA
(Acting) Director, Division of Health Information Dissemination (Proposed)

Editorial and Production Staff

Frederic E. Shaw, MD, JD
Editor, MMWR Series

Suzanne M. Hewitt, MPA
Managing Editor, MMWR Series

Teresa F. Rutledge
Lead Technical Writer-Editor

Jeffrey D. Sokolow, MA
Project Editor

Beverly J. Holland
Lead Visual Information Specialist

Lynda G. Cupell
Malbea A. LaPete
Visual Information Specialists

Quang M. Doan, MBA
Erica R. Shaver
Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman

Virginia A. Caine, MD, Indianapolis, IN

David W. Fleming, MD, Seattle, WA

William E. Halperin, MD, DrPH, MPH, Newark, NJ

Margaret A. Hamburg, MD, Washington, DC

King K. Holmes, MD, PhD, Seattle, WA

Deborah Holtzman, PhD, Atlanta, GA

John K. Iglehart, Bethesda, MD

Dennis G. Maki, MD, Madison, WI

Sue Mallonee, MPH, Oklahoma City, OK

Stanley A. Plotkin, MD, Doylestown, PA

Patricia Quinlisk, MD, MPH, Des Moines, IA

Patrick L. Remington, MD, MPH, Madison, WI

Barbara K. Rimer, DrPH, Chapel Hill, NC

John V. Rullan, MD, MPH, San Juan, PR

Anne Schuchat, MD, Atlanta, GA

Dixie E. Snider, MD, MPH, Atlanta, GA

John W. Ward, MD, Atlanta, GA

CONTENTS

| | |
|--|------|
| Introduction | 1 |
| Methods | 2 |
| Epidemiology of Varicella | 2 |
| Prenatal and Perinatal Exposure | 7 |
| Herpes Zoster Surveillance | 7 |
| Use of Acyclovir to Treat and Prevent Varicella | 8 |
| Vaccines for Prevention of Varicella | 9 |
| Immune Response to Vaccination | 10 |
| Vaccine Efficacy and Vaccine Effectiveness | 13 |
| Breakthrough Disease | 14 |
| Evidence of Immunity | 16 |
| Simultaneous Administration of Vaccines | 17 |
| Economic Analysis of Vaccination | 17 |
| Storage, Handling, and Transportation of Varicella Vaccines | 18 |
| Adverse Events After Vaccination | 19 |
| Transmission of Vaccine Virus | 21 |
| Summary of Rationale for Varicella Vaccination | 22 |
| Recommendations for the Use of Varicella Vaccines | 23 |
| Special Considerations for Vaccination | 24 |
| Health-Care Personnel | 26 |
| Vaccination for Outbreak Control | 27 |
| Contraindications | 27 |
| Precautions | 28 |
| Postexposure Prophylaxis | 29 |
| Acknowledgments | 32 |
| References | 32 |
| Appendix | 38 |
| Continuing Education Activity | CE-1 |

Disclosure of Relationship

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers or commercial services, or commercial supporters. Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

Prevention of Varicella

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Prepared by
Mona Marin, MD, Dalya Güris, MD,* Sandra S. Chaves, MD, Scott Schmid, PhD, Jane F. Seward, MBBS
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC

Summary

Two live, attenuated varicella zoster virus–containing vaccines are available in the United States for prevention of varicella: 1) a single-antigen varicella vaccine (VARIVAX,® Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 1995 for use among healthy children aged ≥12 months, adolescents, and adults; and 2) a combination measles, mumps, rubella, and varicella vaccine (ProQuad,® Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 2005 for use among healthy children aged 12 months–12 years. Initial Advisory Committee on Immunization Practices (ACIP) recommendations for prevention of varicella issued in 1995 (CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1996;45[No. RR-11]) included routine vaccination of children aged 12–18 months, catch-up vaccination of susceptible children aged 19 months–12 years, and vaccination of susceptible persons who have close contact with persons at high risk for serious complications (e.g., health-care personnel and family contacts of immunocompromised persons). One dose of vaccine was recommended for children aged 12 months–12 years and 2 doses, 4–8 weeks apart, for persons aged ≥13 years. In 1999, ACIP updated the recommendations (CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1999;48[No. RR-6]) to include establishing child care and school entry requirements, use of the vaccine following exposure and for outbreak control, use of the vaccine for certain children infected with human immunodeficiency virus, and vaccination of adolescents and adults at high risk for exposure or transmission.

In June 2005 and June 2006, ACIP adopted new recommendations regarding the use of live, attenuated varicella vaccines for prevention of varicella. This report revises, updates, and replaces the 1996 and 1999 ACIP statements for prevention of varicella. The new recommendations include 1) implementation of a routine 2-dose varicella vaccination program for children, with the first dose administered at age 12–15 months and the second dose at age 4–6 years; 2) a second dose catch-up varicella vaccination for children, adolescents, and adults who previously had received 1 dose; 3) routine vaccination of all healthy persons aged ≥13 years without evidence of immunity; 4) prenatal assessment and postpartum vaccination; 5) expanding the use of the varicella vaccine for HIV-infected children with age-specific CD4+T lymphocyte percentages of 15%–24% and adolescents and adults with CD4+T lymphocyte counts ≥200 cells/μL; and 6) establishing middle school, high school, and college entry vaccination requirements. ACIP also approved criteria for evidence of immunity to varicella.

Introduction

Varicella is a highly infectious disease caused by the varicella-zoster virus (VZV). Secondary attack rates for this virus might reach 90% for susceptible household contacts. VZV causes a systemic infection that results typically in lifetime immunity. In otherwise healthy persons, clinical illness after reexposure is rare.

In 1995, a vaccine to prevent varicella (VARIVAX,® Merck & Co., Inc., Whitehouse Station, New Jersey) was licensed in the United States for use among healthy children aged ≥12 months, adolescents, and adults; recommendations of the Advisory Committee on Immunization Practices (ACIP)

* During the preparation of this report, Dalya Güris was an employee with the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC. She presently is employed by Merck, Inc., Whitehouse Station, New Jersey.

The material in this report originated in the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director; and the Division of Viral Diseases, Larry Anderson, MD, Director.

Corresponding preparer: Mona Marin, MD, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE, MS A-47, Atlanta, GA 30333. Telephone: 404-639-8791; Fax: 404-639-8665; E-mail: mmarin@cdc.gov.

regarding use of the varicella vaccine have been published previously (1,2) This report revises, updates, and replaces earlier ACIP statements (Table 1).

Methods

In response to increasing reports of varicella outbreaks among highly vaccinated populations (3–6), ACIP's measles-mumps-rubella and varicella (MMRV) workgroup first met in February 2004 to review data related to varicella vaccine use in the United States since implementation of the vaccination program in 1995 and to consider recommendation options for improving control of varicella disease. The workgroup held monthly conference calls and met in person three times a year. The workgroup reviewed data on the impact of the 1-dose varicella vaccination program, including data on vaccination coverage, changes in varicella epidemiology, transmission from vaccinated persons with varicella, vaccine effectiveness, immune response to vaccination, evidence of immunity, and potential risk factors for vaccine failure. Published and unpublished data related to correlates of protection, safety, immunogenicity, and efficacy[†] of the new quadrivalent MMRV vaccine and the immunogenicity and efficacy of a second dose of varicella vaccine also were reviewed. Cost-benefit and cost-effectiveness analyses were considered, including revised cost-benefit analysis of both the 1- and 2-dose programs for children compared with no vaccination program and the incremental benefit of a second dose. Presentations were made to the full ACIP meetings in October 2004, February 2005, June 2005, and June 2006. Recommendation options were developed and discussed by the MMRV workgroup. When definitive research evidence was lacking, the recommendations incorporated expert opinion of the workgroup members. The workgroup sought input from partner organizations (i.e., the American Academy of Pediatrics [AAP], the American Academy of Family Physicians [AAFP], the American College of Obstetricians and Gynecologists, the Council of State and Territorial Epidemiologists, and the Association of Immunization Managers) and from state public health professionals and immunization program directors. Proposed recommendations and a draft statement were presented to the full ACIP in June 2005 and June 2006. After deliberations, final ACIP recommendations were approved in 2005 and 2006. Modifications to the draft statement were made following CDC and external review process to update and clarify wording in the document.

[†] In this report, efficacy refers to the extent to which a specific intervention produces a beneficial result under ideal conditions.

Epidemiology of Varicella

General

VZV is transmitted from person to person by direct contact, inhalation of aerosols from vesicular fluid of skin lesions of acute varicella or zoster, or infected respiratory tract secretions that also might be aerosolized. The virus enters the host through the upper-respiratory tract or the conjunctiva.

The average incubation period for varicella is 14–16 days[§] after exposure to rash; however, this period can vary (range: 10–21 days). The period of contagiousness of infected persons is estimated to begin 1–2 days before the onset of rash and to end when all lesions are crusted, typically 4–7 days after onset of rash (7). Persons who have progressive varicella (i.e., development of new lesions for >7 days) might be contagious longer, presumably because their immune response is depressed, which allows viral replication to persist. VZV remains dormant in sensory-nerve ganglia and might be reactivated at a later time, causing herpes zoster (HZ) (i.e., shingles), a painful vesicular rash typically appearing in a dermatomal distribution of one or two sensory-nerve roots.

Since implementation of a universal childhood varicella vaccination program in 1995, the epidemiology and clinical characteristics of varicella in the United States have changed, with substantial declines in morbidity and mortality attributable to varicella. No consistent changes in HZ epidemiology have been documented.

Vaccinated persons might develop modified varicella disease with atypical presentation. Varicella disease that develops >42 days after vaccination (i.e., breakthrough varicella) typically is mild, with <50 skin lesions, low or no fever, and shorter (4–6 days) duration of illness. The rash is more likely to be predominantly maculopapular rather than vesicular. Nevertheless, breakthrough varicella is contagious.

Prevaccine Era

Before the introduction of varicella vaccine in 1995, varicella was a universal childhood disease in the United States, with peak incidence in the spring and an average annual incidence of 15–16 cases per 1,000 population. On the basis of data from the National Health Interview Survey (NHIS) for 1980–1990, an average of 4 million cases were estimated to have occurred annually (annual incidence rate: 15 cases per 1,000 population) (8). Varicella was not a nationally notifiable disease when vaccine was introduced in 1995, and surveillance data were limited. In 1994, only 28 states, the District

[§] The en dash in numeric ranges is used to represent inclusive years, hours, days, ages, dosages, or a sequence of numbered items.

TABLE 1. Summary of recommendations of the Advisory Committee on Immunization Practices (ACIP) for prevention of varicella — United States, 1996, 1999, and 2007

| Category | 1996 recommendations | 1999 recommendations | 2007 recommendations |
|---|--|--|--|
| Routine childhood schedules | 1 dose recommended at age 12–18 months | No change | 2 doses recommended <ul style="list-style-type: none"> • 1st dose at age 12–15 months • 2nd dose at age 4–6 years |
| Adults and adolescents aged ≥ 13 years | 2 doses, 4–8 weeks apart Recommended for susceptible persons who have close contact with persons at high risk for serious complications: 1) health-care workers and 2) family contacts of immunocompromised persons Should be considered for susceptible persons at high risk for exposure: 1) persons who live or work in environments in which transmission of VZV is likely (e.g., teachers of young children, child care employees, and residents and staff members in institutional settings), 2) persons who live and work in environments in which transmission can occur (e.g., college students, inmates and staff members of correctional institutions, and military personnel), 3) nonpregnant women of childbearing age, and 4) international travelers. Is desirable for other susceptible adolescents | No change Recommended for susceptible persons at high risk for exposure or transmission: 1) persons who live or work in environments in which transmission of VZV is likely (e.g., teachers of young children, day care employees, and residents and staff members in institutional settings), 2) persons who live and work in environments in which transmission can occur (e.g., college students, inmates and staff members of correctional institutions, and military personnel), 3) nonpregnant women of childbearing age, 4) international travelers, and 5) adolescents and adults living in households with children. No change | 2 doses, 4–8 weeks apart Recommended for all adolescents and adults without evidence of immunity |
| Catch-up vaccination | 1 dose recommended for all susceptible children aged 19 months–12 years (i.e., those with no history of varicella or vaccination) | No change | 2nd dose recommended for all persons who received 1 dose previously |
| HIV*-infected persons | Contraindicated | 2 doses, 3 months apart Should be considered for asymptomatic or mildly symptomatic HIV-infected children in CDC immunologic and clinical categories N1 or A1 with age-specific CD4+ T-lymphocyte percentages $\geq 25\%$ | 2 doses, 3 months apart Should be considered for HIV-infected children with age-specific CD4+ T-lymphocyte percentages $\geq 15\%$ May be considered for adolescents and adults with CD4 counts $\geq 200/\mu\text{L}$. |
| Antenatal screening | None | None | Recommended prenatal assessment and postpartum vaccination |
| Outbreak control vaccination | None | Should be considered | Recommended 2-dose vaccination policy |
| Postexposure vaccination | None | Recommended within 3–5 days | No change |
| Vaccination requirements | None | Recommended for children without evidence of immunity attending child care centers and entering elementary school Should be considered for middle school and junior high school students without other evidence of immunity | Recommended for children attending child care centers, students in all grade levels, and persons attending college or other postsecondary educational institutions |

* Human immunodeficiency virus.

of Columbia, and New York City reported cases to CDC's National Notifiable Disease Surveillance System (NNDSS); reporting was passive, with estimated completeness ranging from <0.1% to 20% (9).

In multiple studies, age-specific incidence data were derived from NHIS and from state and local surveys (8,10,11). During 1980–1990, an estimated 33% of cases occurred among preschool-aged children (i.e., children aged 12 months–4 years), and 44% occurred among school-aged children (i.e., children aged 5–9 years) (annual incidence rates: 82.8 and 91.1 cases per 1,000 children, respectively). Approximately 90%–92% of cases occurred among persons aged <15 years, and cases occurred rarely among persons aged \geq 50 years. However, studies using data from state and local surveys conducted during 1990–1992 and during 1994–1995 indicated that the highest incidence of varicella occurred among preschool-aged rather than school-aged children, indicating that the disease was being acquired at earlier ages (10,11). National seroprevalence data for 1988–1994 indicated that 95.5% of adults aged 20–29 years, 98.9% of adults aged 30–39 years, and >99.6% of adults aged \geq 40 years were immune to VZV (12). However, for reasons that are not well understood, the epidemiology of varicella differs between countries with temperate and tropical climates (13–18). In the majority of countries with temperate climates, >90% of persons are infected by adolescence whereas in countries with tropical climates, a higher proportion of infections are acquired at older ages, which results in higher susceptibility among adults (19).

Estimates of the burden of varicella hospitalization varied according to the year(s) studied, the source of data, and the definitions used for a varicella-related hospitalization (20–23). Estimates were higher if varicella was listed as either a principal or a secondary cause of hospitalization, in which case some incidental varicella hospitalization might have been included. During 1988–1995, an estimated 10,632 hospitalizations were attributable annually to varicella in the United States (range: 8,198–16,586) (20). Another study demonstrated an annual average of 15,073 hospitalizations during 1993–1995, but this period might have included an epidemic year (22). Overall rates of hospitalization for varicella during 1988–1995 ranged from 2.3 to 6.0 cases per 100,000 population. If any varicella-related hospital discharge diagnostic code was included, rates varied between 5.0 and 7.0 cases per 100,000 population (20–23).

During 1988–1995, persons without severe immunocompromising conditions or treatments comprised the largest proportion (89%) of annual varicella-related hospitalizations (20). Before vaccination, children aged \leq 4 years accounted for 43%–44% of hospitalizations, and persons aged \geq 20 years accounted for 32%–33% (20,22). The rate of

complications from varicella was substantially higher for persons aged \geq 20 years and for infants (i.e., children aged <1 year). Adults aged \geq 20 years were 13 times more likely to be hospitalized when they had varicella than children aged 5–9 years, and infants aged <1 year were six times more likely to be hospitalized than children aged 5–9 years (20). The most common complications of varicella that resulted in hospitalizations were skin and soft tissue infections (especially invasive group A streptococcal infections), pneumonia, dehydration, and encephalitis. In 1980, an association was identified between Reye syndrome and the use of aspirin during varicella or influenza-like illness; since then, Reye syndrome, which was once considered a common complication resulting from varicella infection, has become rare (24–26).

During 1970–1994, the average annual number of deaths for which varicella was recorded as the underlying cause was 105; the overall average annual varicella mortality rate was 0.4 deaths per 1 million population. The age distribution of varicella deaths has shifted during this period. During 1970–1974, persons aged <20 years accounted for 80% of varicella deaths, compared with 46% during 1990–1994. During 1970–1994, the average case-fatality rate (CFR) for varicella for all ages combined ranged from 2.0 to 3.6 per 100,000 cases, with higher rates among infants and adults aged \geq 20 years (27). Although CFRs declined substantially during this period, the risk for varicella-related death during 1990–1994 was still 25 times higher for adults than for children aged 12 months–4 years (CFR: 21.3 and 0.8 per 100,000 cases, respectively). During the same period, 89% of varicella deaths among children and 75% of varicella deaths among adults occurred in persons without severe underlying immunocompromising medical conditions. The most common complications among persons who died of varicella were pneumonia, central nervous system complications (including encephalitis), secondary infection, and hemorrhagic conditions. A recent reanalysis of varicella deaths also considered varicella when listed as a contributing cause of death in addition to the underlying cause studied in the previous report (28). During 1990–1994, a varicella diagnosis was listed on an average of 145 death certificates per year (105 as an underlying cause and 40 as a contributing cause), with an overall annual varicella mortality rate of 0.6 deaths per 1 million population.

Varicella during pregnancy can have adverse consequences for the fetus and infant, including congenital varicella syndrome (see Prenatal and Perinatal Exposure). Reliable data on the number of cases of congenital varicella syndrome are not available. However, on the basis of age-specific varicella incidence (from NHIS), the annual number of births, and the risk for congenital varicella syndrome (1.1% overall risk in the first 20 weeks of pregnancy), 44 cases of congenital

varicella syndrome are estimated to have occurred each year in the United States during the prevaccine era (29).

Postvaccine Era


In 1995, a varicella vaccine (VARIVAX,[®] Merck & Co., Inc., Whitehouse Station, New Jersey) was licensed in the United States for use among healthy children aged ≥ 12 months, adolescents, and adults. At that time, ACIP recommended routine varicella vaccination of children aged 12–18 months, catch-up vaccination of susceptible children aged 19 months–12 years, and vaccination of susceptible persons who have close contact with persons at high risk for serious complications (e.g., health-care workers and family contacts of immunocompromised persons) (1; Table 1). In 1999, ACIP updated the recommendations to include child care and school entry requirements, use of the vaccine after exposure and for outbreak control, use of the vaccine for certain children infected with human immunodeficiency virus (HIV), and vaccination of adolescents and adults at high risk for exposure or transmission (2; Table 1).

During 1997–2005, national varicella vaccination coverage among children aged 19–35 months increased from 27% to 88%, with no statistically significant difference in coverage by race or ethnicity (30). In 2005, state-specific varicella vaccination coverage ranged from 69% to 96% (31). National surveillance data continue to be limited, but passive surveillance data in certain states have documented a decline in varicella incidence.

In four states (Illinois, Michigan, Texas, and West Virginia) with adequate ($\geq 5\%$ of expected cases during 1990–1994) reporting to NNDSS, varicella incidence for 2004 declined 53%–88% compared with the average incidence for 1990–1994, with vaccination coverage among children aged 19–35 months ranging from 82% to 88% (32; CDC, unpublished data, 2006). During 2003–2005, the number of cases increased in Illinois and Texas; the biggest increase (56%) occurred in Texas (Figure 1). The number of cases remained stable in Michigan (Figure 1) and declined minimally in West Virginia.

In 1995, along with implementation of the national vaccination program, CDC instituted active surveillance for varicella in three communities (Antelope Valley, California; Travis County, Texas; and West Philadelphia, Pennsylvania) in collaboration with state and local health departments to establish baseline data and to monitor trends in varicella disease after introduction of varicella vaccine. By 2000, vaccination coverage among children 19–35 months in these three communities had reached 74%–84%, and reported total varicella cases had declined 71%–84% (33). Although incidence declined to the greatest extent (83%–90%) among children aged 12 months–4 years, incidence declined in all age groups, including infants and adults, indicating the herd immunity effects of the vaccination program. Since 2001, only two sites were funded to continue surveillance (Antelope Valley and West Philadelphia). By 2005, vaccination coverage in these two sites had increased to 90%, and the reduction in incidence had reached 90% and 91%, respectively (34). During

FIGURE 1. Number of reported cases of varicella disease among persons of all age groups* and estimated annual vaccination coverage among children aged 19–35 months,[†] by year and state — Michigan and Texas, 1990–2005



*Source: National Notifiable Disease Surveillance System.


†Source: National Immunization Survey.

1996–2005, as vaccination coverage continued to increase, the proportion of persons with varicella who had been vaccinated increased from 2% to 56%. During 1995–2004, peak incidence for varicella cases in active surveillance sites shifted from age 3–6 years to age 9–11 years.

After introduction of vaccine in 1995, the number and rate of annual varicella-related hospitalizations declined. In one study of a nationally representative sample that was conducted during 1993–2001, varicella hospitalizations declined 75% (22). In another study, the annual varicella-related hospitalization rate declined 88% during 1994–2002 (23) (Figure 2). Hospitalization rates declined 100% among infants, and substantial declines also were recorded in all other age groups (up to age 50 years); hospitalization rates declined 91% among children aged <10 years, 92% among children and adolescents aged 10–19 years, and 78% among adults aged 20–49 years. The greater decline in hospitalizations among children led to an increase in the proportion of varicella-related hospitalizations among adults (40% of hospitalizations in 2002 occurred among persons aged ≥ 20 years) (23). In the combined active surveillance area, varicella-related hospitalizations declined from 2.4–4.2 hospitalizations per 100,000 population during 1995–1998 to 1.5 per 100,000 population in 2000 (33) and to 0.8 per 100,000 population in 2005 (34).

During 1995–2001, the number of deaths for which varicella was listed as the underlying cause decreased from 115 to 26 (28) (Figure 3). Since then, the number of deaths declined further; 16 deaths were reported in 2003. Age-adjusted mortality rates decreased 66%, from an average of 0.41 deaths per 1 million population during 1990–1994 to 0.14 during 1999–2001. The decline was observed in all age groups <50 years,

FIGURE 2. Varicella-related* hospitalization rates† among persons aged <50 years, by year and age group — United States, 1994–2002




Source: Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. *JAMA* 2005;294:797–802.

* Varicella was the primary diagnosis code.

† Per 100,000 population.

FIGURE 3. Varicella-related mortality rates,* by year and underlying and contributing cause of death — United States, 1990–2001



Source: Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. *N Engl J Med* 2005;352:450–8.

* Per 1 million population.

with the greatest reduction (92%) occurring among children aged 12 months–4 years (0.09 deaths per 1 million population), followed by an 88% reduction among children aged 5–9 years (0.10 deaths per 1 million population). Deaths among persons aged ≥ 50 years did not decline to the same extent; however, the validity of reported varicella deaths in this age group is low (35), and the majority of these deaths are not considered to be caused by varicella. During 1999–2001, the average rate of mortality attributed to varicella among all racial and ethnic populations was <0.15 deaths per 1 million persons. Persons without high-risk conditions (e.g., malignancies, HIV/acquired immunodeficiency syndrome [AIDS], and other immune deficiencies) accounted for 92% of deaths attributable to varicella. The average rates of deaths for which varicella was listed as a contributing cause of death also declined during 1999–2001, compared with 1990–1994.

Despite high 1-dose vaccination coverage and the success of the vaccination program in reducing varicella morbidity and mortality, reports to CDC from active surveillance sites and from states with well-implemented vaccination programs and surveillance indicate that in certain states and in one active surveillance site, the number of reported varicella cases has remained constant or declined minimally, and outbreaks have continued to occur. During 2001–2005, outbreaks were reported in schools with high varicella vaccination coverage (range 96%–100%) (3,4). The outbreaks were similar in certain respects: 1) all occurred in elementary schools, 2) vaccine effectiveness was similar (range: 72%–85%), 3) the highest attack rates occurred among the younger students, 4) each outbreak lasted approximately 2 months, and 5) index cases occurred among vaccinated students (although their disease was mild). Overall attack rates among vaccinated children varied (range: 11%–17%), with attack rates in certain classrooms as high as 40%. These data indicate that even in settings in

which vaccination coverage was nearly universal and vaccine performed as expected, the 1-dose vaccination program could not prevent varicella outbreaks completely.

Prenatal and Perinatal Exposure

In the prevaccine era, prenatal infection was uncommon because the majority of women of childbearing age were immune to VZV (12,36). Varicella in pregnant women is associated with a risk for VZV transmission to the fetus or newborn. Intrauterine VZV infection might result in congenital varicella syndrome, neonatal varicella, or HZ during infancy or early childhood (37–46). Infants who are exposed prenatally to VZV, even if asymptomatic, might have measurable varicella-specific IgM antibody during the newborn period, have persistent varicella-specific IgG immunity after age 1 year without a history of postnatal varicella, or demonstrate positive lymphocyte transformation in response to VZV antigen (37).

Congenital varicella syndrome was first recognized in 1947 (40). Congenital varicella syndrome can occur among infants born to mothers infected during the first half of pregnancy and might be manifested by low birthweight, cutaneous scarring, limb hypoplasia, microcephaly, cortical atrophy, chorioretinitis, cataracts, and other anomalies. In one study, incidence of congenital varicella syndrome was calculated using aggregate data from nine cohort studies carried out during 1986–2002 (47). Rates were 0.6% (4 of 725) for 2–12 weeks' gestation, 1.4% (9 of 642) for 13–28 weeks, and 0 (0 of 385) after 28 weeks.

In a prospective study of 1,373 mothers with varicella during pregnancy conducted in the United Kingdom and West Germany during 1980–1993, the highest risk (2%) for congenital varicella syndrome was observed when maternal infection occurred during 13–20 weeks' gestation (43). The risk was 0.4% after maternal infection during 0–12 weeks' gestation. No cases of congenital varicella syndrome occurred among the infants of 366 mothers with HZ during pregnancy. Nine isolated cases involving birth defects consistent with congenital varicella syndrome have been reported after maternal varicella beyond 20 weeks' gestation (with the latest occurring at 28 weeks) (47,48). In a prospective study, HZ occurred during infancy or early childhood in four (0.8%) of 477 infants who were exposed to VZV during 13–24 weeks' gestation and in six (1.7%) of 345 infants who were exposed during 25–36 weeks' gestation (43).

The onset of varicella in pregnant women from 5 days before to 2 days after delivery results in severe varicella infection in an estimated 17%–30% of their newborn infants. These infants are exposed to VZV without sufficient maternal

antibody to lessen the severity of disease. The risk for neonatal death has been estimated to be 31% among infants whose mothers had onset of rash ≤ 4 days before giving birth (45). This estimate was made on the basis of a limited number of infant deaths and might be higher than the actual risk because the study was performed before neonatal intensive care was available. In addition, certain cases were not part of prospective studies but were reported retrospectively, making the results subject to selection bias. When these cases were reevaluated subsequently by another investigator, certain infants were demonstrated to have been at higher risk for death because of low birthweight; in at least one case, another cause of death was probable (46). Varicella-zoster immune globulin (VZIG) has been reported to reduce incidence of severe neonatal varicella disease (49) and therefore is indicated in such situations. Nevertheless, the risk for death among neonates who do not receive postexposure prophylaxis with VZIG is likely to be substantially lower than was estimated previously.

Herpes Zoster Surveillance

After primary infection, VZV persists as a latent infection in sensory-nerve ganglia. The virus can reactivate, causing HZ. Mechanisms controlling VZV latency are not well understood. Risk factors for HZ include aging, immunosuppression, and initial infection with varicella in utero or during early childhood (i.e., age <18 months). An estimated 15%–30% of the general population experience HZ during their lifetimes (50,51); this proportion is likely to increase as life expectancy increases. The most common complication of HZ, particularly in older persons, is postherpetic neuralgia (PHN), the persistence of sometimes debilitating pain weeks to months after resolution of HZ. Life-threatening complications of HZ also can occur; these include herpes ophthalmicus, which can lead to blindness. Another severe manifestation is dissemination, which might involve generalized skin eruptions, and central nervous system, pulmonary, hepatic, and pancreatic complications. Dissemination, pneumonia, and visceral involvement typically are restricted to immunocompromised persons. VZV can be transmitted from the lesions of patients who have HZ to susceptible contacts. Although few data are available to assess this risk, one household contact study reported that the risk for VZV transmission from HZ was approximately 20% of the risk for transmission from varicella (52).

Varicella vaccination might alter the risk for HZ at the level of both the individual and the population (i.e., herd immunity). Just as wild-type VZV can cause wild-type HZ, attenuated vaccine virus has the potential to become latent and later reactivate to cause vaccine virus strain (also called Oka-strain) HZ (53). Multiple studies have evaluated the risk for Oka-strain

HZ after vaccination of immunocompromised or healthy children (54–58). In a study of leukemic children, the rate of HZ after a mean 4.1 years of follow-up (range: 6 months–10 years) was 2% in vaccine recipients and 15% in controls with a history of varicella (54). A subset of 96 of these vaccine recipients was matched prospectively according to chemotherapeutic protocol with 96 leukemic children who had experienced natural varicella. Analysis indicated that the incidence of HZ was approximately three times lower in vaccine recipients (0.80 per 100 person-years) than in the matched leukemic children who had experienced natural varicella (2.46 per 100 person-years) ($p = 0.01$). Data for healthy children are more limited, and findings might be influenced by multiple factors (e.g., incomplete ascertainment, limited duration of follow up or no follow up of subjects of older ages, no comprehensive screening for wild-type varicella infection before or after vaccination, or lack of testing all cases to distinguish Oka- from wild-type HZ). Nonetheless, these studies suggest that the risk for Oka-strain HZ after a single dose of varicella vaccine is lower than that after wild-type varicella infection (56–58). Over time, the risk for and manifestation of Oka-strain HZ should be examined in older persons who are at greater risk for HZ complications. Persons who experience varicella infection before vaccination (i.e., as a result of in utero or unapparent infection) or after vaccination (i.e., as a result of breakthrough infection) presumably are latently infected with two strains of VZV. The risk for HZ in these persons is unknown. No long-term studies have been conducted that compare the risk for Oka-strain HZ in persons who receive 1 dose of varicella vaccine with the risk for those who receive 2 doses.

Varicella vaccination also might change the risk for HZ at the population level. With the development of herd immunity and reduction in the likelihood of exposure, the varicella vaccination program prevents wild-type VZV infection among vaccine recipients and nonvaccine recipients, eliminating the risk for wild-type HZ in these persons. Reduction in the likelihood of wild-type varicella infection also increases the median age for acquiring varicella (although age-specific incidence rates themselves are lower). This reduces the risk for varicella infection during early childhood (i.e., age <18 months), thereby reducing a risk factor for childhood HZ.

Exposure of persons with latent wild-type VZV infection to persons with varicella is thought to boost specific immunity, which might contribute to controlling reactivation of VZV and the development of HZ (50). Concern has been expressed that by providing fewer opportunities for varicella exposure among persons with previous wild-type varicella infection, reduction in the likelihood of exposure might increase the risk for HZ, possibly within as few as 5 years after

introduction of varicella vaccination (59) and reaching a vaccination coverage of >90%.

Herpes zoster is not a nationally notifiable disease in the United States, and HZ surveillance has been conducted using multiple methods, study sites, or data sources. For certain studies, baseline data were available before the start of the varicella vaccination program. One study that included baseline data was a retrospective analysis of electronic medical records from a health maintenance organization (HMO) during 1992–2002 (60). This HMO study indicated that age-adjusted incidence of HZ remained stable during 1992–2002 as incidence of varicella decreased (60). Age-adjusted and -specific annual incidence rates of HZ fluctuated slightly over time; the age-adjusted rate was highest in 1992, at 4.1 cases per 1,000 person-years, and was 3.7 cases per 1,000 person-years in 2002. For other studies initiated in the postvaccine era, baseline data are not available (61–63). An analysis of national incidence data from the Medstat database (available at <http://www.medstat.com/Products/view/?id=71>) demonstrated an overall incidence of HZ in 2000 and 2001 of 3.2 (95% confidence interval [CI] = 3.1–3.2) per 1,000 person-years (61), representing no increase in age-adjusted HZ in the past 20 years in the United States compared with earlier published data (64). Data from two HMOs in Oregon and Washington for 1997–2003 indicated no statistically significant increase in HZ incidence rates except among children aged 10–17 years (relative risk [RR] = 1.12, CI = 1.05–1.18); these increases were attributed to increased use of oral steroids (62). Another study of data gathered from a statewide telephone survey during 1999–2003 in Massachusetts demonstrated an increase in HZ (63). Age groups particularly affected included persons aged 25–44 years and those aged >65 years. Finally, in the two active varicella surveillance sites (Antelope Valley, California, and West Philadelphia, Pennsylvania), active surveillance for HZ in children aged <20 years has been ongoing since 2000. During 2000–2004, incidence of HZ in children aged <10 years declined significantly ($p < 0.05$) from 0.75 to 0.23 cases per 1,000 children (65; CDC unpublished data, 2006). In summary, multiple studies and surveillance data demonstrate no consistent trends in HZ incidence in the United States since implementation of the varicella vaccination program in 1995.

Use of Acyclovir to Treat and Prevent Varicella

Acyclovir is a synthetic nucleoside analog that inhibits replication of human herpes viruses, including VZV. Since the early 1980s, intravenous acyclovir has been available to treat

immunocompromised persons who have varicella. When administered within 24 hours of onset of rash, acyclovir has been demonstrated to be effective in reducing varicella-associated morbidity and mortality in this population (66–68).

In 1992, the Food and Drug Administration (FDA) approved the use of oral acyclovir for the treatment of varicella in otherwise healthy children. This approval was made on the basis of placebo-controlled, double-blind studies (69,70) that demonstrated the beneficial clinical effects (i.e., a decrease in the number of days in which new lesions appeared, the duration of fever, and the severity of cutaneous and systemic signs and symptoms) that occurred when acyclovir was administered within 24 hours of rash onset. No serious adverse events occurred during the period of drug administration. Administration of acyclovir did not decrease transmission of varicella or reduce the duration of absence from school. Because few complications occurred (1%–2%), these studies could not determine whether acyclovir had a statistically significant effect on disease severity among healthy children. In these studies, antibody titers after infection in children receiving acyclovir did not differ substantially from titers of children in the control group (69,70). Clinical trials among adolescents and adults have indicated that acyclovir is well-tolerated and effective in reducing the duration and severity of clinical illness if the drug is administered within 24 hours of rash onset (71–73).

In 1993, AAP's Committee on Infectious Diseases published a statement regarding the use of acyclovir (74). AAP did not consider administration of acyclovir to healthy children to have clinical benefit sufficient to justify its routine administration; however, AAP stated that certain circumstances might justify its use. AAP recommended that oral acyclovir should be considered for otherwise healthy persons at increased risk for moderate to severe varicella (e.g., persons aged >12 years, persons with chronic cutaneous or pulmonary disorders, persons receiving long-term salicylate therapy, and persons receiving short, intermittent, or aerosolized courses of corticosteroids). Certain experts also recommend use of oral acyclovir for secondary case-patients who live in the same households as infected children (74).

Acyclovir is classified as a Category B drug in the FDA use-in-pregnancy rating. Although studies involving animals have not indicated teratogenic effects, adequate, well-controlled studies in pregnant women have not been conducted. However, a prospective registry of acyclovir use during pregnancy that collected data on outcomes of 596 infants whose mothers were exposed to systemic acyclovir during the first trimester of pregnancy indicated that the rate and types of birth defects approximated those in the general population (75). AAP has not recommended routine use of oral acyclovir for pregnant

women because the risks and benefits to the fetus and mother were unknown. However, in instances of serious, viral-mediated complications (e.g., pneumonia), AAP has recommended that intravenous acyclovir should be considered (74).

Two nucleoside analogs, acyclovir and famciclovir, have been approved by FDA for treating HZ. If administered within 72 hours of rash onset, acyclovir has accelerated the rate of cutaneous healing and reduced the severity of acute pain in adults who have HZ (76). Oral famciclovir, when administered during the same period, has similar efficacy (77).

Acyclovir is not indicated for prophylactic use among otherwise healthy children, adolescents, or adults without evidence of immunity after exposure to varicella. Vaccination is the method of choice in these situations. No studies have been conducted regarding prophylactic use of acyclovir among immunocompromised persons; therefore, VZIG is recommended in these situations.

Vaccines for Prevention of Varicella

Two live attenuated varicella virus vaccines are licensed in the United States for prevention of varicella: single-antigen varicella vaccine (VARIVAX,[®] Merck & Co., Inc., Whitehouse Station, New Jersey) and combination MMRV vaccine (ProQuad,[®] Merck & Co., Inc., Whitehouse, New Jersey). Both vaccines are derived from the Oka strain of live, attenuated VZV. The Oka strain was isolated in Japan (78) in the early 1970s from vesicular fluid in a healthy child who had natural varicella and was attenuated through sequential propagation in cultures of human embryonic lung cells, embryonic guinea-pig cells, and human diploid cells (WI-38). The virus in the Oka/Merck vaccine has undergone further passage through human diploid-cell cultures (MRC-5) for a total of 31 passages.

In 1995, the single-antigen varicella vaccine was licensed in the United States for use among healthy persons aged ≥12 months. This vaccine is lyophilized; when reconstituted as directed in the package insert and stored at room temperature for a maximum of 30 minutes, it contains a minimum of 1,350 plaque forming units (PFUs) of Oka/Merck VZV in each 0.5 mL dose (79). Each dose also contains 12.5 mg of hydrolyzed gelatin, trace amounts of neomycin and fetal bovine serum, 25 mg of sucrose, and trace residual components of MRC-5 cells (including DNA and protein). The vaccine does not contain preservatives. Since 1995, >55 million doses have been distributed in the United States. Reporting of serious adverse events has been rare (see Vaccine-Associated Adverse Events).

In 2005, the combination MMRV vaccine was licensed in the United States for use among healthy children aged 12 months–12 years. The attenuated measles, mumps, and

rubella vaccine viruses in ProQuad[®] are identical and of equal titer to those in the measles, mumps, and rubella (MMR) vaccine, MMRII[®] (80). The titer of Oka/Merck VZV is higher in MMRV than in single-antigen varicella vaccine, a minimum of 3.99 log₁₀ PFUs compared with 1,350 PFUs (approximately 3.13 log₁₀) in each 0.5 mL dose. The other constituents are similar to those in the single-antigen varicella vaccine.

Immune Response to Vaccination

In clinical trials of the single-antigen varicella vaccine conducted before licensure, seroconversion was assessed using lots of vaccine with different amounts of PFUs and laboratory assays with different levels of sensitivity and specificity. Using a specially developed, sensitive gp-enzyme-linked immunosorbent assay (ELISA) test that is not available commercially, seroconversion (defined by the acquisition of any detectable varicella antibodies >0.3 gpELISA units) was observed at approximately 4–6 weeks after vaccination with 1 dose of varicella vaccine in approximately 97% of 6,889 susceptible children aged 1–12 years (79). The seroconversion rate was 98% for children aged 12–15 months and 95% among those aged 5–12 years (81). Adolescents aged 13–17 years had a lower seroconversion rate (79%) after a single dose of vaccine. A study performed postlicensure used fluorescent antibody to membrane antigen (FAMA) titers 16 weeks after vaccination to assess serologic response and demonstrated that 61 (76%) of 80 healthy child vaccine recipients seroconverted (FAMA titers ≥1:4) after 1 dose of single-antigen varicella vaccine (82).

Primary antibody response to the vaccine at 6 weeks postvaccination is correlated with protection against disease (83,84). In clinical trials, rates of breakthrough disease were lower among children with varicella antibody titers of ≥5 gpELISA units than among those with titers of <5 units (84); children with a 6-week postvaccination antibody titer of <5 gpELISA units were 3.5 times more likely to have breakthrough varicella than those with a titer of ≥5 gpELISA units. Later studies of immunogenicity (85) have reported the proportion of vaccinated children who achieved this antibody level instead of seroconversion. After 1 dose of the single-antigen varicella vaccine, 86% of children had gpELISA levels of ≥5 units/mL (85). Studies performed using FAMA indicated that a titer >1:4 at 16 weeks postvaccination is correlated with protection against disease (82). Of healthy persons with a titer of >1:4 at 16 weeks post vaccination, <1% have had varicella after a household exposure (n = 130). In contrast, the attack rate among those with a titer of <1:4 was 55% (n = 60).

Persistence of antibody in children after 1 dose of single-antigen varicella vaccine was demonstrated in both short- and long-term follow-up studies. In a clinical study, the rate of antibody persistence detected by gpELISA was nearly 100% after 9 years of follow-up for 277 children (85). Another study demonstrated that although antibody titers (detected by FAMA) might decline 12–24 months after vaccination, the median titer did not change after 1–4 years and even rose after 10 years (86). In Japan, VZV antibodies were present in 37 (97%) of 38 children who received varicella vaccine 7–10 years earlier (with titers comparable to those of 29 children who had had natural varicella infection within the previous 10 years) (87) and in 100% of 25 children when followed for as long as 20 years (i.e., antibody levels were higher than those observed 10 years earlier) (88). Interpretation of long-term studies is complicated by at least two factors. First, asymptomatic boosting of vaccine-induced immunity by exposure to wild-type VZV is likely. Because varicella vaccine is not routinely recommended in Japan, coverage of children was estimated to be low (approximately 20%) during 1991–1993. Second, sample sizes were limited as a result of the decrease in the number of children followed-up with increasing time since vaccination.

The second dose of varicella vaccine in children produced an improved immunologic response that is correlated with improved protection. A comparative study of healthy children who received 1 or 2 doses of single-antigen varicella vaccine administered 3 months apart indicated that a second dose provided higher antibody levels as measured by the proportion of subjects with titers of ≥5 gpELISA units and by geometric mean titers (GMTs) and higher efficacy (85; Tables 2–4). The proportion of subjects with antibody titers of ≥5 gpELISA units in the 2-dose recipients was higher 6 weeks after the second dose than after the first dose (99.6% and 85.7%, respectively) and remained high at the end of the 9-year follow-up period, although the difference between the two regimens narrowed (97% and 95%, respectively). GMT 6 weeks after the second dose was substantially higher than that after a single dose (142 and 12, respectively). The difference in GMTs between the two regimens did not persist over 9 years of follow-up among subjects who seroconverted after vaccination, although GMTs in both regimens remained high by the end of the study period. However, receipt of a second dose decreased the rate of breakthrough varicella significantly (3.3-fold) and increased vaccine efficacy (p<0.001). Another study that assessed the immunogenicity of a second dose received 4–6 years after the first dose demonstrated a substantial increase in antibody levels in the first 7–10 days in the majority of those tested, indicating an anamnestic response.

TABLE 2. Humoral and cellular immune response among children aged 12 months–12 years measured at 6 weeks postvaccination, by vaccine type and vaccination schedule — United States, 1988–2002

| Immune response | 6 wks after dose 1 | | 6 wks after dose 2 and 3 mos between doses | | 6 wks after dose 2 at age 4–6 yrs | |
|----------------------------|-----------------------|---------|---|---------|--------------------------------------|---------|
| | Varicella vaccine* | MMRV† | Varicella vaccine | MMRV | Varicella vaccine | MMRV |
| VZV§ IgG gpELISA¶ ≥5 µ/mL | 85.7%** | 91.2%†† | 99.6%** | 99.2%†† | 99.4%§§ | 98.9%§§ |
| GMT¶¶ VZV IgG gpELISA µ/mL | 12.5** | 13.0†† | 142.6** | 588†† | 212.4§§ | 317§§ |
| Mean SI*** | 28.6 (+/-6.2)††† | | 36.9 (+/-9.1)††† | | 58.6 (+/-6.5)§§§ | |

* Single-antigen varicella vaccine.

† Combination measles, mumps, rubella, and varicella vaccine.

§ Varicella zoster virus.

¶ Enzyme-linked immunosorbent assay.

** **Source:** Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. *Pediatr Infect Dis J* 2004;23:132–7.

†† **Source:** Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. *Pediatr Infect Dis J* 2005;24:665–9.

§§ **Source:** Reisinger KS, Hoffman Brown ML, Xu J, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-Ril and Varivax. *Pediatrics* 2006;117:265–72.

¶¶ Geometric mean titer.

*** Stimulation index. Mean SIs from different laboratories and from different studies should not be directly compared.

††† **Source:** Nader S, Bergen R, Sharp M, Arvin A. Comparison of cell-mediated immunity (CMI) to varicella-zoster virus (VZV) in children and adults immunized with live attenuated varicella vaccine. *J Infect Dis* 1995;171:13–7.

§§§ **Source:** Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. *J Infect Dis* 1995;172:217–9.

TABLE 3. Ten-year efficacy of single-antigen varicella vaccine in preventing varicella after community exposure among children aged 12 months–12 years, by number of vaccine doses — United States, 1993–2003

| No. doses | No. study subjects | No. cases | Average annual rate* of varicella | | | Community exposure 10-year efficacy | |
|-----------|-----------------------|-----------|--------------------------------------|---------|--|--|-----------|
| | | | Observed among vaccine recipients | | Estimated among nonimmune children† | % | CI |
| | | | % | CI§ | % | | |
| 1 | 1,104 | 60 | 0.8 | 0.6–1.0 | 14.2 | 94.4 | 92.9–95.7 |
| 2 | 1,017 | 17 | 0.2 | 0.1–0.4 | 14.0 | 98.3 | 97.3–99.0 |

* Per 100 children aged 12 months–12 years.

† Estimated rates among nonimmune children were age-adjusted and based on historic data from unvaccinated susceptible children who had exposure in the community.

§ 95% confidence interval.

Source: Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. *Pediatr Infect Dis J* 2004;23:132–7.

TABLE 4. Ten-year efficacy of single-antigen varicella vaccine in preventing varicella after household exposure among children aged 1–12 years, by number of vaccine doses — United States, 1993–2003

| No. doses | No. children with household exposure | No. cases | Average annual rate* of varicella | | | Household exposure 10-year efficacy | |
|-----------|--|-----------|--------------------------------------|------|--|--|-----|
| | | | Observed among vaccine recipients | | Estimated among nonimmune children† | % | CI§ |
| | | | (%) | (%) | (%) | | |
| 1 | 94 | 8 | 8.5 | 86.8 | 90.2 | 83.7–96.7 | |
| 2 | 96 | 3 | 3.1 | 86.8 | 96.4 | 92.4–100.0 | |

* Per 100 children aged 12 months–12 years.

† Rate among non-immune children is estimated on the basis of historic secondary-attack rates in unvaccinated, susceptible household contacts.

§ 95% confidence interval.

Source: Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. *Pediatr Infect Dis J* 2004;23:132–7.

On the day of the second dose, GMT was 25.7, compared with 143.6 GMT 7–10 days after the second dose; 60% of recipients had at least a fourfold increase in antibody titers, and an additional 17% had at least a twofold increase (89). Three months after the second dose, GMT remained higher than on the day of second dose (119.0 and 25.7, respectively). Among children, VZV antibody levels and GMTs after 2 doses administered 4–6 years apart were comparable to those obtained when the 2 doses were administered 3 months apart.

The combination MMRV vaccine was licensed on the basis of noninferiority of immunogenicity of the antigenic components compared with MMR and varicella vaccines administered concomitantly at separate injection sites rather than on clinical efficacy (80). Clinical studies of healthy children aged 12–23 months indicated that those who received 1 dose of MMRV vaccine had levels of antibody to measles, mumps, rubella, and varicella similar to levels of children who received 1 dose of MMR and 1 dose of varicella vaccines concomitantly at separate injection sites. For the varicella component in MMRV, 91.2% (CI = 87.0%–94.4%) of children achieved antibody titers of ≥ 5 gpELISA units/mL 6 weeks after vaccination (90). A subgroup of children received a second dose of MMRV vaccine approximately 3 months after the first dose. The serologic response (≥ 5 gpELISA units/mL) after 2 doses was 99.2% (CI = 97.0%–99.9%) (Table 2). Also, GMT for varicella after the second dose of MMRV vaccine increased approximately forty-onefold (90). Administration of combination MMRV vaccine to healthy children aged 4–6 years who had been vaccinated previously with MMR and single-antigen varicella vaccines resulted in similar antibody levels and a twenty-fivefold increase in GMT levels (91).

Among persons aged ≥ 13 years, multiple studies have described seroconversion rates after receipt of the single-antigen varicella vaccine (range: 72%–94% after 1 dose and 94%–99% after a second dose administered 4–8 weeks later) (79,92,93). In clinical studies, detectable antibody levels have persisted for at least 5 years in 97% of adolescents and adults who were administered 2 doses of vaccine 4–8 weeks apart (79). However, other studies demonstrated that 25%–31% of adult vaccine recipients who seroconverted lost detectable antibodies (by FAMA) at multiple intervals (range: 1–11 years) after vaccination (93,94). For persons who had breakthrough disease after exposure to varicella, the severity of illness or the attack rates did not increase over time (95).

Innate (i.e., nonspecific) and adaptive (i.e., humoral and cellular) immunity are important in the control of primary varicella infection. The capacity to elicit cell-mediated immunity is important for viral clearance, providing long-term

protection against disease and preventing symptomatic VZV reactivation. Studies among children and adults have indicated that breakthrough varicella typically is mild, even among vaccine recipients without seroconversion or vaccine recipients who lost detectable antibody, suggesting that VZV-specific cell-mediated immunity affords protection to vaccine recipients in the absence of a detectable antibody response (94,95). Studies of the cellular immune response to vaccination among children demonstrated that immunization with 1 dose of varicella vaccine induced VZV-specific T-cell proliferation that was maintained in 26 (90%) of 29 children 1 year postvaccination and in 52 (87%) of 60 children 5 years postvaccination (96). In this study, the mean stimulation index (SI), a marker of cell-mediated immunity, was 12.1 after 1 year and 22.1 after 5 years. Data obtained at 1 year postvaccination from a subset of children in a precensure study comparing the immune response among children who received 1 and 2 doses administered 3 months apart demonstrated that the varicella-specific lymphocyte proliferation responses were significantly higher for recipients of 2 doses than for recipients of 1 dose (mean SI: 34.7 and 23.1, respectively; $p = 0.03$) (97). In the study of the 2 doses administered 4–6 years apart, results also indicated that the lymphocyte proliferation response was significantly higher at 6 weeks and 3 months after the second dose than at the same time points after the first dose ($p < 0.01$) (89; Table 2).

Among adults, vaccine-induced VZV-specific T-cell proliferation was maintained in 16 (94%) of 17 subjects 1 and 5 years postvaccination (96,98). The mean SI was 9.9 after 1 year and 22.4 after 5 years.

Correlates of Protection

For children, the varicella antibody response measured by gpELISA 6 weeks postvaccination correlates with neutralizing antibody level, VZV-specific T-cell proliferative responses, vaccine efficacy, and long-term protection against varicella after exposure to VZV (83,84,99,100). A titer of ≥ 5 gpELISA units/mL is associated with protection against disease although it should not be considered an absolute guarantee of protection. Breakthrough cases have occurred among children with ≥ 5 gpELISA units/mL. A FAMA titer $\geq 1:4$ at 16 weeks postvaccination also correlates with protection against disease (82). However, neither of these antibody tests is available commercially. The relationship between the antibody level measured at other intervals postvaccination, especially immediately prior to exposure and breakthrough disease has not been studied. No correlates of protection have been evaluated for adults.

Vaccine Efficacy and Vaccine Effectiveness

One-Dose Regimen

Prelicensure Efficacy

In prelicensure studies carried out among children aged 12 months–14 years, the protective efficacy of single-antigen varicella vaccine varied, depending on the amount of live virus administered per dose, the exposure setting (community or household), and the quality and length of the clinical follow-up. The majority of the prelicensure studies reported efficacy of 1 dose of varicella vaccine within the range of 70%–90% against any clinical disease and 95% against severe disease for 7–10 years after vaccination (81,101,102). A randomized placebo-controlled efficacy trial was conducted among children aged 12 months–14 years, but the formulation differed from that of the current vaccine (17,000 PFUs per dose (103,104), with follow-up of children through 7 years postvaccination (105). Reported efficacy was 100% at 1 year and 98% at 2 years after vaccination, and 100% and 92%, respectively, after exposures to VZV that occurred in the household. Although a randomized control study was not conducted for adults, the efficacy of single-antigen varicella vaccine was determined by evaluation of protection when adult vaccine recipients were exposed to varicella in the household. On the basis of the reported historical attack rate of 87% for natural varicella after household exposure among unvaccinated children, estimated efficacy among adults was approximately 80% (79). The attack rate of unvaccinated adults exposed in households was not studied.

Postlicensure Efficacy and Effectiveness

Prevention of All Varicella Disease

Postlicensure studies have assessed the effectiveness⁴ of the single-antigen varicella vaccine under field conditions in child care, school, household, and community settings using multiple methods. Effectiveness frequently has been estimated against all varicella and also against moderate and severe varicella (defined in different ways). Outbreak investigations have assessed effectiveness against clinically defined varicella. The majority of these investigations have demonstrated vaccine effectiveness for prevention of varicella in the same range described in prelicensure trials (70%–90%) (3–6,106–113), with some lower (44%, 56%) (114,115) and some higher (100% in one of two schools investigated) estimates (107). A

⁴ In this report, effectiveness refers to the extent to which a specific intervention, when deployed in the field, does what it is intended to do for a defined population.

retrospective cohort study in 11 childcare centers demonstrated vaccine effectiveness of 83% for prevention of clinically diagnosed varicella (116). In a case-control study that measured vaccine effectiveness against laboratory-confirmed varicella in a pediatric office setting during 1997–2003, vaccine effectiveness was 85% (CI = 78%–90%) during the first four years and 87% (CI = 81%–91%) for the entire study period (117,118). Finally, in a study of household secondary attack rates, considered the most robust test of vaccine performance because of the intensity of exposure, varicella vaccine was 79% (CI = 70%–85%) effective in preventing clinically defined varicella in exposed household contacts aged 12 months–14 years without a history of varicella disease or vaccination (119). Postlicensure data on vaccine effectiveness against all disease have been summarized (Table 5).

In a randomized clinical trial conducted postlicensure that compared the efficacy of 1 dose of varicella vaccine with that of 2 doses, the estimated vaccine efficacy for 1 dose for a 10-year observation period was 94.4% (CI = 92.9%–95.7%) (85; Table 3). In the same study, the efficacy of 1 dose of vaccine in preventing varicella after household exposure for 10 years was 90.2% (CI = 83.7%–96.7%) (Table 4). This study did not use placebo controls and used historic data for attack rates in unvaccinated children to calculate vaccine efficacy.

Prevention of Moderate and Severe Varicella

Postlicensure studies assessing vaccine performance in preventing moderate and severe varicella have consistently demonstrated high effectiveness. Definitions for disease severity have varied among studies. Certain studies have used a defined scale of illness that included the number of skin lesions, fever, complications, and investigator assessment of illness severity, and others have used only the number of skin lesions, reported complications, or hospitalizations.

TABLE 5. Summary of postlicensure data on effectiveness of single-antigen varicella vaccine against disease among children aged 12 months–14 years — United States, 1996–2004

| Against all disease (%) | Against moderate and severe disease* | | No. estimates |
|-------------------------|--------------------------------------|-------|---------------|
| | No. estimates | (%) | |
| <70 | 2 | <70 | 0 |
| 70–79 | 4 | 70–79 | 0 |
| 80–89 | 13 | 80–89 | 1 |
| ≥90 | 1 | ≥90 | 16 |

* Definitions of severity differed among studies. Typically, cases were considered to be moderate for persons who had either 50–500 or 250–500 lesions and severe for persons who had >500 lesions or who either were hospitalized or had a serious complication (e.g., skin or soft tissue infections). Two early studies defined severe disease as having >200 or >250 lesions. In another study, severity of disease was defined according to a modified disease severity score from the clinical trials.

Moderate varicella typically has been defined as either 50–500 or 250–500 lesions, and severe varicella has been defined as >500 lesions or any hospitalization or complication. In the randomized postlicensure clinical trial, severe varicella was defined as >300 lesions and fever of $\geq 102^{\circ}\text{F}$ (38.9°C), oral equivalent. Regardless of different definitions, multiple studies have demonstrated that single-antigen varicella vaccine was $\geq 95\%$ effective in preventing combined moderate and severe disease (3–6,85,106,107,109–113,115–119); one study demonstrated effectiveness of 86% (114). Effectiveness was 100% against severe disease when measured separately (6,85,109,111,117,119). Postlicensure data on vaccine effectiveness against moderate and severe varicella have been summarized (Table 5).

Two-Dose Regimen

In a randomized clinical trial of single-antigen varicella vaccine that compared the efficacy of 1 dose with that of 2 doses administered 3 months apart, the estimated vaccine efficacy of 2 doses for a 10-year observation period was 98.3% (CI = 97.3%–99.0%), which was significantly higher than efficacy after 1 dose ($p < 0.001$) (85; Table 5). The 2-dose regimen also was 100% efficacious against severe varicella. In the same study, the efficacy of 2 doses of single-antigen varicella vaccine in preventing disease after household exposure over 10 years was 96.4% (CI = 92.4%–100%), not significantly different from 1 dose (90.2%) ($p = 0.112$) (Table 4). However, the number of cases involving household exposure was limited.

Formal studies to evaluate the clinical efficacy of the combination MMRV vaccine have not been performed. Efficacy of the individual components was established previously in clinical studies with the single-antigen vaccines.

Breakthrough Disease

Breakthrough disease is defined as a case of infection with wild-type VZV occurring >42 days after vaccination. In clinical trials, varicella disease was substantially less severe among vaccinated persons than among unvaccinated persons, who usually have fever and several hundred vesicular lesions (120). In cases of breakthrough disease, the median number of skin lesions is commonly <50 (99,121–123). In addition, compared with unvaccinated persons, vaccine recipients have had fewer vesicular lesions (lesions more commonly are atypical, with papules that do not progress to vesicles), shorter duration of illness, and lower incidence of fever.

Multiple postlicensure investigations also have demonstrated that the majority of breakthrough varicella cases are signifi-

cantly milder than cases among unvaccinated children ($p < 0.05$) (3,5,107–114,116–118,124). However, approximately 25%–30% of breakthrough cases are not mild, with clinical features more similar to those in unvaccinated children (124). Since 1999, when varicella deaths became nationally notifiable, two deaths from breakthrough varicella disease have been reported to CDC; one of a girl aged 9 years with a history of asthma who was receiving steroids when she had the breakthrough infection, and the other of a girl aged 7 years with a history of malignant ependymoma who also was under steroid therapy at the time of her death (CDC, unpublished data, 2006).


One-Dose Regimen

In clinical trials, 1,114 children aged 1–12 years received 1 dose of single-antigen varicella vaccine containing 2,900–9,000 PFUs of attenuated virus per dose and were actively followed for up to 10 years postvaccination (79). Among a subset of 95 vaccine recipients with household exposure to varicella, eight (8%) reported a mild form of varicella (10–34 lesions).

In a randomized clinical trial that compared the efficacy of 1 dose of vaccine to that of 2 doses during a 10-year observation period, the cumulative rate of breakthrough varicella among children who received 1 dose was 7.3% (85). Breakthrough cases occurred annually in 0.2%–2.3% of recipients of 1 dose of vaccine. Cases occurred throughout the observation period, but the majority were reported 2–5 years after vaccination (Figure 4). Of 57 children with breakthrough cases, 13 (23%) had >50 lesions.

In cross-sectional studies, the attack rate for breakthrough disease has ranged between 11% and 17% (and as high as 40% in certain classrooms) in outbreak investigations (3) and 15% in household settings (119).

FIGURE 4. Cumulative breakthrough rates* for 1 and 2 doses of single-antigen varicella vaccine among children aged 12 months–12 years, by number of years after vaccination — United States, 1993–2003



Source: Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. *Pediatr Infect Dis J* 2004;23:132–7.

* Per 100 person-years at risk.

Two-Dose Regimen

Data Among Children

In a randomized clinical trial that compared the efficacy of 1 dose of vaccine with that of 2 doses, the cumulative rate of breakthrough varicella during a 10-year observation period was 3.3-fold lower among children who received 2 doses than that among children who received 1 dose (2.2% and 7.3, respectively; $p < 0.001$) (85). Breakthrough cases occurred occasionally in 0.8% of 2-dose vaccine recipients. The majority of cases of breakthrough disease occurred 2–5 years after vaccination; no cases were reported 7–10 years after vaccination (Figure 4). Of 16 children with breakthrough cases, three (19%) had >50 lesions. The proportion of children with >50 lesions did not differ between the 1-dose and 2-dose regimens ($p = 0.5$).

Breakthrough Infections Among Adolescents and Adults

In postlicensure studies of adolescents and adults who received 2 doses, 40 (9%) cases of breakthrough varicella occurred among 461 vaccine recipients who were followed for 8 weeks–11.8 years (mean: 3.3 years) after vaccination (95), and 12 (10%) cases occurred among 120 vaccine recipients who were followed for 1 month–20.6 years (mean: 4.6 years) (94). One prelicensure study of persons who had received 2 doses of vaccine reported that 12 (8%) breakthrough cases had occurred among 152 vaccine recipients who were followed for 5–66 months (mean: 30 months) postvaccination (93).

Contagiousness

Prelicensure clinical trials reported the rate of disease transmission from vaccinated persons with varicella cases to their vaccinated siblings. In 10 trials that were conducted during 1981–1989, breakthrough infections occurred in 114 (5.3%) of 2,163 vaccinated children during the 1–8 year follow-up period of active surveillance, and secondary transmission occurred to 11 (12.2%) of their 90 vaccinated siblings (121). Illness was mild in both index and secondary case-patients. Household transmission from a vaccinated child with breakthrough disease to a susceptible adult (one of whom died) have been reported (CDC, unpublished data, 2006). One study examined secondary attack rates from vaccinated and unvaccinated persons with varicella to both vaccinated and unvaccinated household contacts aged 12 months–14 years (119). This study demonstrated that vaccinated persons with varicella with <50 lesions were only one third as contagious as unvaccinated persons with varicella. However, vaccinated

persons with varicella who had ≥ 50 lesions were as contagious as unvaccinated persons with varicella (119). Vaccinated persons with varicella tend to have milder disease, and, although they are less contagious than unvaccinated persons with varicella, they might not receive a diagnosis and be isolated. As a result, they might have more opportunities to infect others in community settings, thereby further contributing to VZV transmission. Vaccinated persons with varicella also have been index case-patients in varicella outbreaks (3,4,115).

Risk Factors for Vaccine Failure

Potential risk factors for vaccine failure have been identified in studies of vaccine effectiveness during outbreak investigations and other specially designed studies (5,108–110,113–115,118,125). In outbreak investigations, the low number of cases limits the ability of researchers to conduct multivariate analyses and examine the independent effect of each risk factor for vaccine failure. An increased risk for breakthrough disease has been noted with decreasing age at vaccination, with a threefold increase in breakthrough disease risk for children vaccinated at age <14 months (110), an increase of twofold in one study and nearly fourfold in another for children vaccinated at age <16 months (108,115), and a ninefold increase for children vaccinated at age <19 months (113). Other outbreak investigations have demonstrated that time since vaccination (variably defined as ≥ 3 , >5 , or ≥ 5 years) was associated with an increased risk for breakthrough disease (relative risk [RR] = 2.6, 6.7, and 2.6, respectively) (5,114,115). However, age at vaccination and time since vaccination are highly correlated, and their independent association with the risk for breakthrough disease has been assessed in only one outbreak investigation (113). A retrospective cohort study that adjusted for other potential risk factors demonstrated an increased risk for breakthrough disease for children vaccinated at age <15 months (adjusted relative risk [aRR] = 1.4; CI = 1.1%–1.9%) (125). A case-control study demonstrated that the effectiveness of vaccine in the first year after vaccination was significantly lower (73%) among children vaccinated at age <15 months than it was among children vaccinated at age ≥ 15 months (99%) ($p = 0.01$) (118). However, the difference in the overall effectiveness between children vaccinated at these ages was not statistically significant for subsequent years (8 years of follow-up) (81% and 88%, respectively; $p = 0.17$). Active surveillance data collected during 1995–2004 from a sentinel population of 350,000 persons were analyzed to determine whether the severity and annual incidence of breakthrough varicella cases increased with time since vaccination (126). Children vaccinated >5 years previously were 2.6 times more likely to have moderate and severe breakthrough

varicella than those vaccinated <5 years previously ($p = 0.016$). The annual rates of breakthrough varicella among children aged 12 months–12 years increased significantly with time since vaccination after adjusting for the effects of age at infection, age at vaccination, and year of infection ($p < 0.01$).

Multiple other studies that examined possible reasons for lower vaccine effectiveness did not find age at vaccination (3–5, 111, 114) or time since vaccination (3, 110, 111) to be associated with vaccine failure. An ongoing study is examining these factors and risk for vaccine failure (127). After 8 years of active follow-up of 7,449 children vaccinated at age 12–23 months, results do not indicate an increased risk for breakthrough disease among children vaccinated at age 12–14 months compared with those vaccinated at age 15–23 months. Moreover, a test for trend revealed no change in the rate of reported breakthrough disease for each additional month of age at vaccination (127).

Two outbreak investigations noted an increased risk for breakthrough disease in children with asthma and eczema (109, 113). In these investigations, the use of steroids to treat asthma or eczema was not studied. Steroids have been associated previously with severe varicella in unvaccinated persons (128–130). Only one retrospective cohort study controlled simultaneously for the effect of multiple risk factors, including the use of steroids, and this study demonstrated no association of risk for breakthrough disease with asthma or eczema (125). However, this study documented an increased risk for breakthrough disease if the child had received a prescription of oral steroids (considered a proxy for taking oral steroids when exposed to varicella) within 3 months of breakthrough disease (adjusted RR [aRR] = 2.4; CI = 1.3%–4.4%) and when varicella vaccination was administered within 28 days of MMR vaccine (aRR = 3.1; CI = 1.5%–6.4%).

Evidence of Immunity

ACIP has approved criteria for evidence of immunity to varicella (Box). Only doses of varicella vaccines for which written documentation of the date of administration is presented should be considered valid. Neither a self-reported dose nor a history of vaccination provided by a parent is, by itself, considered adequate evidence of immunity. Persons who lack documentation of adequate vaccination or other evidence of immunity should be vaccinated.

Historically, self-reporting of varicella disease by adults or by parents for their children has been considered valid evidence of immunity. The predictive value of a self-reported positive disease history was extremely high in adults in the prevaccine era although data on positive predictive value are lacking in parental reports regarding their children (131–133).

BOX. Evidence of immunity to varicella

Evidence of immunity to varicella includes any of the following:

- documentation of age-appropriate vaccination with a varicella vaccine
 - preschool-aged children (i.e., aged ≥ 12 months): 1 dose
 - school-aged children, adolescents, and adults: 2 doses*
- laboratory evidence of immunity[†] or laboratory confirmation of disease
- birth in the United States before 1980[§]
- diagnosis or verification of a history of varicella disease by a health-care provider[¶]
- diagnosis or verification of a history of herpes zoster by a health-care provider

* For children who received their first dose at age <13 years and for whom the interval between the 2 doses was ≥ 28 days, the second dose is considered valid.

[†] Commercial assays can be used to assess disease-induced immunity, but they lack sensitivity to always detect vaccine-induced immunity (i.e., they might yield false-negative results).

[§] For health-care personnel, pregnant women, and immunocompromised persons, birth before 1980 should not be considered evidence of immunity.

[¶] Verification of history or diagnosis of typical disease can be provided by any health-care provider (e.g., school or occupational clinic nurse, nurse practitioner, physician assistant, or physician). For persons reporting a history of, or reporting with, atypical or mild cases, assessment by a physician or their designee is recommended, and one of the following should be sought: 1) an epidemiologic link to a typical varicella case to a laboratory-confirmed case or 2) evidence of laboratory confirmation, if it was performed at the time of acute disease. When such documentation is lacking, persons should not be considered as having a valid history of disease because other diseases might mimic mild atypical varicella.

As disease incidence decreases and the proportion of vaccinated persons with varicella having mild cases increases, varicella will be less readily recognized clinically. A recent study demonstrated that only 75% of unvaccinated children aged 12 months–4 years who reported a positive history of varicella were in fact immune (confirmed by serological testing), compared with 89% of children aged 5–9 years and 10–14 years (134). To limit the number of false-positive reports and ensure immunity, ACIP recommends that evidence of immunity should be either a diagnosis of varicella by a health-care provider or a health-care provider verification of a history of disease rather than parental or self-reporting. The above-cited study demonstrated that 99% of persons aged 15–19 years and 100% of those aged 20–29 years who reported a history of varicella were immune (134). Because serologic evidence of VZV infection has been documented in 96%–97% of U.S.-born adults aged 20–29 years and in 97%–99% of adults aged ≥ 30 years tested during 1998–1999 (12), U.S. birth before 1980 is considered evidence of immunity except for health-care personnel (HCP), pregnant women, and

immunocomprised persons. For these three groups, certainty regarding immunity is desirable because of the possibility of nosocomial transmission to high-risk patients; transmission of the virus to the fetus, which might result in congenital varicella syndrome; and the possibility of severe disease. Post-vaccination serologic testing to verify an immune response to varicella vaccine is not routinely recommended because available commercial assays lack sensitivity in detecting vaccine-induced immunity and might give false negative results.

Simultaneous Administration of Vaccines

Single-antigen varicella vaccine is well-tolerated and effective in healthy children aged ≥ 12 months when administered simultaneously with MMR vaccine either at separate sites and with separate syringes or separately ≥ 4 weeks apart. The number and types of adverse events occurring in children who have received VARIVAX and MMRII concurrently have not differed from those in children who have been administered the vaccines at different visits (79,135). Data concerning the effect of simultaneous administration of VARIVAX with vaccines containing various combinations of MMR, diphtheria and tetanus toxoids and pertussis (DTP), and *Haemophilus influenzae* type b (Hib) have not been published (79). A randomized study of 694 subjects determined that the immune response to MMR, varicella, and Hib vaccines administered concurrently with a fourth dose of pneumococcal conjugate vaccine (PCV7) was not inferior to that of those vaccines when administered without PCV7; the percentage of subjects who seroconverted was $>90\%$ for all antigens for both groups (136).

Concomitant administration of the combination MMRV vaccine with other vaccines also has been assessed. In a clinical trial involving 1,913 healthy children aged 12–15 months, three groups were compared (137). One group received concomitantly administered (at separate sites) MMRV vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed (DTaP), Hib conjugate (meningococcal protein conjugate) vaccine, and hepatitis B (recombinant) (Hep B) vaccine. The second group received MMRV vaccine at the initial visit, followed by DTaP, Hib, and Hep B vaccines administered concomitantly 6 weeks later. The third group received MMR and varicella vaccines concomitantly followed 6 weeks later by DTaP, Hib, and Hep B vaccines. Seroconversion rates and antibody titers were comparable for the measles, mumps, rubella, and varicella components for the first two groups. No immunologic data were reported for the third group. The Hib and Hep B seroconversion rates for the two groups that received those vaccines also were comparable.

Data are absent or limited for the concomitant use of MMRV vaccine with inactivated polio, pneumococcal conjugate, influenza, and hepatitis A vaccines. Simultaneous administration of the majority of widely used live and inactivated vaccines has produced seroconversion rates and rates of adverse reactions similar to those observed when the vaccines are administered separately. Therefore, single-antigen and combination MMRV vaccines may be administered simultaneously with other vaccines recommended for children aged 12–15 months and those aged 4–6 years. Simultaneous administration is particularly important when health-care providers anticipate that, because of certain factors (e.g., previously missed vaccination opportunities), a child might not return for subsequent vaccination.

Economic Analysis of Vaccination

A cost-effectiveness analysis was performed before initiation of the varicella vaccination program in the United States (138). The results of the study indicated a savings of \$5.40 for each dollar spent on routine vaccination of preschool-aged children when direct and indirect costs were considered. When only direct medical costs were considered, the benefit-cost ratio was 0.9:1.0. Benefit-cost ratios were only slightly lower when lower estimates of the short- and long-term effectiveness of the vaccine were used.

A recent analysis was performed that used current estimates of morbidity and mortality (20,28,33) and current direct and indirect costs (ACIP, unpublished presentation, 2006). The model considered that the second dose will reduce varicella disease residual after the first dose by 79%. From a societal perspective, both 1-dose and 2-dose vaccination programs are cost saving compared with no program. The vaccine program cost was estimated at \$320 million for 1 dose and \$538 million for 2 doses. The savings from varicella disease prevented were estimated at approximately \$1.3 billion for the 1-dose program and approximately \$1.4 billion for the 2-dose program. Compared with the 1-dose program, the incremental cost for the second dose was estimated to be \$96,000 per quality-adjusted life year (QALY) saved. If benefits from preventing group A streptococcus infections and HZ among vaccinated persons are added, incremental costs per QALY saved are \$91,000 and \$17,000, respectively. Because of the uncertainty of the modeled predictions of an increase in HZ among persons with a history of varicella and the fact that no consistent trends demonstrate an increase in HZ attributable to the varicella vaccination program in the United States, HZ among persons with a history of varicella was not included in the model.

Storage, Handling, and Transportation of Varicella Vaccines

Single-antigen varicella and combination MMRV vaccines have similar but not identical distribution, handling, and storage requirements (79,80). For potency to be maintained, the lyophilized varicella vaccines must be stored frozen at an average temperature of 5°F (-15°C) or colder. Household freezers manufactured since the mid-1980s are designed to maintain temperatures from -4°F (-20°C) to 5°F (-15°C). When tested, VARIVAX has remained stable in frost-free freezers. Freezers that reliably maintain an average temperature of <5°F (<-15°C) and that have a separate sealed freezer door are acceptable for storing VARIVAX and ProQuad. Health-care providers may use stand-alone freezers or the freezer compartment of refrigerator-freezer combinations, provided that the freezer compartment has its own separate, sealed, and insulated exterior door. Units with an internal freezer door are not acceptable. Temperatures should be documented at the beginning and end of each day. Providers should document the required temperature in a newly purchased unit for a minimum of 1 week before using it to store vaccine and routinely thereafter. When varicella vaccines are stored in the freezer compartment of a combined refrigerator-freezer, temperatures in both compartments should be monitored carefully. Setting the thermostat low enough for storage of varicella-containing vaccines might inadvertently expose refrigerated vaccines to freezing temperatures. Refrigerators with ice compartments that either are not tightly enclosed or are enclosed with unsealed, uninsulated doors (e.g., small, dormitory-style refrigerators) are not acceptable for the storage of varicella vaccines.

Diluent should be stored separately either at room temperature or in the refrigerator. Vaccines should be reconstituted according to the directions in the package insert and only with the diluent supplied with the vaccine, which does not contain preservative or other antiviral substances that could inactivate the vaccine virus. Once reconstituted, vaccine should be used immediately to minimize loss of potency. Vaccine should be discarded if not used within 30 minutes after reconstitution.

Handling and Transportation of Varicella Vaccines Within Off-Site Clinics

When an immunization session is being held at a site distant from the freezer in which the vaccine is stored, the number of vaccine vials needed for the immunization session should be packed in either a vaccine shipping container (as received from the manufacturer) or in an insulated cooler, with an

adequate quantity of dry ice (i.e., a minimum of 6 lbs per box) to preserve potency. When placed in a suitable container, dry ice will maintain a temperature of $\leq 5^{\circ}\text{F}$ ($\leq -15^{\circ}\text{C}$). Dry ice should remain in the container upon arrival at the clinic site. If no dry ice remains when the container is opened at the receiving site, the manufacturer (Merck and Company, Inc.) should be contacted for guidance (telephone: 1-800-982-7482). If dry ice is available at the receiving site, it may be used to store vaccine. Thermometers or temperature indicators cannot be used in a container with dry ice. Diluent should not be transported on dry ice.

If dry ice is not available, only single-antigen varicella vaccine may be transported, with frozen packs to keep the temperatures between 36°F–46°F (2°C–8°C). Transport temperatures should be monitored, and a temperature indicator or thermometer should be placed in the container and checked on arrival. The container should be kept closed as much as possible during the immunization session; temperatures should be checked and recorded hourly. If the temperature remains between 36°F–46°F (2°C–8°C), the single-antigen varicella vaccine may be used for up to 72 hours after its removal from the freezer. The date and time should be marked on the vaccine vial. Single-antigen varicella vaccine stored at refrigerated temperatures for any period of time may not be refrozen for future use.

Transportation and storage of combination MMRV vaccine at temperatures between 36°F–46°F (2°C–8°C) is not permissible for any length of time. In contrast to single-antigen varicella vaccine, combination MMRV vaccine must be maintained at temperatures of $\leq 5^{\circ}\text{F}$ ($\leq -15^{\circ}\text{C}$) until the time of reconstitution and administration. This difference in vaccine storage temperatures must be considered when planning off-site clinics. For this reason, transportation of MMRV vaccine to off-site clinics is not advised. If any concerns arise regarding the storage of single-antigen varicella or combination MMRV vaccines, the manufacturer should be contacted for guidance.

Minimizing Wastage of Vaccine

Vaccine wastage can be minimized by accurately determining the number of doses needed for a given patient population. To ensure maximal vaccine potency, smaller shipments of vaccine should be ordered more frequently (preferably at least once every 3 months). Single-antigen varicella vaccine should not be distributed to providers who do not have the capacity to store it properly in a freezer until it is used. Transportation of varicella vaccine should be kept to a minimum to prevent loss of potency. Off-site clinic sites should receive only such amounts of vaccine as they can use within a short time (72 hours if storing single-antigen varicella vaccine at refrigerated temperatures).

Adverse Events After Vaccination

Because adverse events after vaccination might continue to be caused by wild-type VZV even as varicella disease declines, health-care providers should obtain event-appropriate clinical specimens (e.g., cerebrospinal fluid for encephalitis, bronchial lavage or lung biopsy for pneumonia) for laboratory evaluation, including strain identification. Information regarding strain identification is available from Merck's VZV Identification Program (telephone: 1-800-652-6372) or from CDC's National Varicella Reference Laboratory (telephone: 404-639-0066; e-mail: vzvlab@cdc.gov) or at <http://www.cdc.gov/nip/diseases/varicella/surv/default.htm>. Commercial laboratories do not have the capability for strain identification.

The National Vaccine Injury Act of 1986 requires physicians and other health-care providers who administer vaccines to maintain permanent immunization records and to report occurrences of adverse events for selected vaccines, including varicella vaccines. Serious adverse events (i.e., all events requiring medical attention) suspected to have been caused by varicella vaccines should be reported to the Vaccine Adverse Event Reporting System (VAERS). Forms and instructions are available at <https://secure.vaers.org/vaersDataEntryintro.htm>, in the FDA Drug Bulletin at <http://www.fda.gov/medwatch>, or from the 24-hour VAERS information recording at 1-800 822-7967.

Prelicensure

Single-Antigen Varicella Vaccine

Single-antigen varicella vaccine was well-tolerated when administered to >11,000 healthy children, adolescents, and adults during prelicensure clinical trials. In a double-blind, placebo-controlled study among 914 susceptible healthy children aged 12 months–14 years, the only statistically significant ($p < 0.05$) adverse events reported that were more common among vaccine recipients than among placebo recipients were pain and redness at the injection site (103). This study also described the presence of unspecific rash among 2% of placebo and 4% of vaccine recipients occurring within 43 days of vaccination. Of the 28 reported rashes, 10 (36%) were examined by a physician; among those that were examined, four of the seven noninjection site rashes in vaccine recipients were judged to be varicella-like, compared with none of the rashes in the placebo recipients.

In a study comparing the safety of 1 dose of single-antigen varicella vaccine with that of 2 doses administered 3 months apart, no serious adverse events related to vaccination were reported among approximately 2,000 healthy subjects aged 12 months–12 years who were followed for 42 days after

each injection. The 2-dose vaccine regimen was generally well-tolerated, and its safety profile was comparable to that of the 1-dose regimen. Incidence of injection site complaints observed ≤ 3 days after vaccination was slightly higher after dose 2 (25.4%) than after dose 1 (21.7%). Incidence of systemic clinical complaints was lower after dose 2; fever incidence from days 7–21 was 7% after dose 1 and 4% after dose 2 ($p = 0.009$), and varicelliform rash incidence after dose 1 was 3%, compared with 1% after dose 2 ($p = 0.008$), with peak occurrence 8–21 days after vaccination (139).

In uncontrolled trials of persons aged ≥ 13 years, approximately 1,600 vaccine recipients who received 1 dose of single-antigen varicella vaccine and 955 who received 2 doses of vaccine were monitored for 42 days for adverse events (79). After the first and second doses, 24.4% and 32.5% of vaccine recipients, respectively, had complaints regarding the injection site. Varicella-like rash at the injection site occurred in 3% of vaccine recipients after the first injection and in 1% after the second. A nonlocalized rash occurred in 5.5% of vaccine recipients after the first injection and in 0.9% of vaccine recipients after the second, at a peak of 7–21 and 0–23 days postvaccination, respectively.

Combination MMRV Vaccine

In clinical trials, combination MMRV vaccine was administered to 4,497 children aged 12–23 months without concomitant administration with other vaccines (80). The safety profile of the first dose was compared with the safety of MMRII vaccine and VARIVAX administered concomitantly at separate injection sites. The follow-up period was 42 days postvaccination. Systemic vaccine-related adverse events were reported at a statistically significantly greater rate in persons who received MMRV vaccine than in persons who received the two vaccines administered concomitantly at separate injection sites: fever ($\geq 102^\circ\text{F}$ [$\geq 38.9^\circ\text{C}$] oral equivalent), (21.5% and 14.9%, respectively), and measles-like rash (3.0% and 2.1%, respectively). Both fever and measles-like rash usually occurred within 5–12 days after the vaccination, were of short duration, and resolved with no long-term sequelae. Pain, tenderness, and soreness at the injection site were reported at a statistically significantly lower rate in persons who received the combination MMRV vaccine (22.0%) than in those who received MMRII and VARIVAX vaccines (26.7%). Rash at the injection site was more frequent among recipients of 1-dose MMRV vaccine (2.3%) than among recipients of the two vaccines administered separately as first doses (1.5%). A study that also compared use of MMRV with MMRII and VARIVAX administered as a first dose demonstrated similar results (90). During days 5–12, children in the group that received MMRV had higher rates of elevated temperatures

than those in the group that received MMRII and VARIVAX (27.7% and 18.7%, respectively; $p = 0.034$).

To demonstrate that MMRV vaccine could be administered as a second dose, a study was conducted involving 799 children aged 4–6 years who had received primary doses of MMRII and VARIVAX vaccines, either concomitantly or not, at age ≥ 12 months and ≥ 1 month before study enrollment (91). These children were vaccinated randomly (with MMRV and placebo, MMR and placebo, or MMRII and VARIVAX) and then monitored for safety. No serious vaccine-related adverse experiences were reported. Overall, the proportions of subjects with one or more adverse event were comparable among groups receiving MMRV, MMRII, and MMRII and VARIVAX. The group receiving MMRV vaccine had a statistically significantly greater proportion of subjects with erythema ($p = 0.01$) and swelling ($p = 0.008$) at the injection site 1–5 days after vaccination. Another study examined the safety of 2 doses of MMRV administered 3 months apart to 480 children aged 12–23 months (90). The rate of adverse events typically was lower after the second dose of MMRV than after the first dose. The incidence of varicella-like rashes was lower after a second dose of MMRV than after concomitant administration of MMRII and VARIVAX vaccines (0.0% and 1.9%, respectively; $p = 0.01$).

Postlicensure

During March 1, 1995–December 31, 2005, a total of 47.7 million doses of varicella vaccine were distributed in the United States, and 25,306 adverse events that occurred after varicella vaccine administration were reported to VAERS, 1,276 (5%) of which were classified as serious. The overall adverse event reporting rate was 52.7 cases per 100,000 doses distributed. The rate of reporting of serious adverse events was 2.6 per 100,000 doses distributed. Half of all adverse events reported occurred among children aged 12–23 months (VAERS, unpublished data, 2006).

Not all adverse events that occur after vaccination are reported, and many reports describe events that might have been caused by confounding or unrelated factors (e.g., medications and other diseases). Because varicella disease continues to occur, wild-type virus might account for certain reported events. For serious adverse events for which background incidence data are known, VAERS reporting rates are lower than expected after natural varicella or than background rates of disease in the community. Inherent limitations of passive safety surveillance impede comparing adverse event rates after vaccination reported to VAERS with those from complications after natural disease. Nevertheless, the magnitude of these differences suggests that serious adverse events occur at a

substantially lower rate after vaccination than after natural disease. This assumption is corroborated by the substantial decline in the number of severe complications, hospitalizations, and deaths related to varicella that have been reported since implementation of the varicella vaccination program (22,23,28).

Similar to the prelicensure experience, postlicensure safety surveillance data after administration of single-antigen varicella vaccine indicated that rash, fever, and injection-site reactions were the most frequently reported adverse events (140,141). Using these reports from passive surveillance of adverse events during the first 4 years of the vaccination program, when wild-type VZV was still circulating widely, polymerase chain reaction (PCR) analysis confirmed that the majority of rash events occurring within 42 days of vaccination were caused primarily by wild-type varicella-zoster virus. Rashes from the wild-type virus occurred a median of 8 days after vaccination (range: 1–24 days), whereas rashes from the vaccine strain occurred a median of 21 days after vaccination (range: 5–42 days) (140).

As part of postmarketing evaluation of the short-term safety of VARIVAX, 89,753 vaccinated adults and children were identified from automated clinical databases of hospitals, emergency room visits, and clinic visits during April 1995–December 1996 (56). Out of all potential adverse events identified, no consistent time association or clustering of any events was noted during the exposure follow-up period. No cases of ataxia or encephalitis were identified after receipt of varicella vaccine in this group of vaccine recipients. In the prevaccine era, among children aged <15 years, acute cerebellar ataxia was estimated to occur at a rate of one in 4,000 varicella cases, and varicella encephalitis without ataxia was estimated to occur at one in 33,000 varicella cases (142).

Severe complications that are laboratory-confirmed to be caused by vaccine virus strain are rare and include pneumonia (140), hepatitis (143), severe disseminated varicella infection (140,141,144,145), and secondary transmission from five vaccine recipients (140,146–148). Except for the secondary transmission cases, these cases all occurred in immunocompromised patients or in persons who had other serious medical conditions that were undiagnosed at the time of vaccination.

Although other serious adverse events have been reported, vaccine strain involvement was not laboratory-confirmed. Thrombocytopenia (140,141,149) and acute cerebellar ataxia (140,141,150) have been described as potentially associated with single-antigen varicella vaccine. Two children had acute hemiparesis diagnosed after varicella vaccination (one at 5 days and the other at 3 weeks) (151). In both cases, unilateral

infarction of the basal ganglia and internal capsule was noted; this distribution is consistent with varicella angiopathy. Urticaria after varicella vaccine has been associated with gelatin allergy (152). Recurrent papular urticaria has been reported to be potentially associated with varicella vaccination (153). However, available data regarding the potential adverse events after varicella vaccination are insufficient to determine a causal association. The quality of reported information varies widely, and simultaneous administration with other vaccines (especially MMR) might confound attribution.

Herpes Zoster. Similar to wild-type VZV, vaccine virus can establish latent infection and subsequently reactivate, causing HZ disease in vaccine recipients. Before vaccine licensure, studies in children with leukemia had demonstrated a much lower rate of HZ in vaccinated children compared with those (age and protocol matched) with previous varicella (54). Cases of HZ in healthy vaccine recipients have been confirmed to be caused by both vaccine virus and wild-type virus, suggesting that certain HZ cases in vaccine recipients might result from antecedent natural varicella infection that might not have been detected by the patient or from infection after vaccination (140). A single case has been reported of a child who received a diagnosis of neuroblastoma and had severe chronic zoster attributed to vaccine virus strain that with time became drug resistant (145). A large postlicensure safety study performed through surveys conducted every 6 months and validated by medical chart review in the first 9 years of a 15-year follow-up study of >7,000 enrolled children vaccinated with single-antigen varicella vaccine at age 12–24 months estimated HZ disease incidence to be 22 per 100,000 person-years (CI = 13–37) as reported by parents (Steven Black, MD, Northern California Kaiser Permanente Medical Care Program, unpublished presentation, 2005). The incidence of HZ was 30 per 100,000 person-years among healthy children aged 5–9 years (154) and 46 per 100,000 person-years for those aged ≤ 14 years (64). However, these rates are drawn from different populations and based on different methodologies. In addition, a proportion of children in these age groups would not have experienced varicella disease; those rates are likely to underestimate rates in a cohort of children all infected with wild-type VZV, making direct comparison difficult with a vaccinated cohort.

Transmission of Vaccine Virus

Results from prelicensure vaccine trials of the single-antigen varicella vaccine suggest that transmission of varicella vaccine virus from healthy persons to susceptible contacts is rare. This risk was assessed in siblings of healthy vaccinated children who themselves received placebo (103). Six (1%) of

439 placebo recipients seroconverted without rash; the vaccinated siblings of these six children also did not develop rash. Serologic data suggested that three of these six seroconverters received vaccine mistakenly in lieu of their siblings. In a smaller study, immunocompromised siblings of healthy children receiving varicella vaccine were evaluated clinically and by testing for humoral or cell-mediated immune responses (155). No evidence was demonstrated of vaccine virus transmission to any of 30 immunocompromised siblings from 37 healthy children receiving varicella vaccine.

Accumulated data from postlicensure surveillance activities suggest that the risk for transmission of varicella vaccine virus from healthy persons to susceptible contacts is low. With >55 million doses of VARIVAX distributed since licensure, transmission from immunocompetent persons after vaccination has been documented by PCR analysis from only five persons, resulting in six secondary infections, all of them mild (140,146–148). Three episodes involved transmission from healthy children aged 1 year to healthy household contacts, including a sibling aged 4 months, a father, and a pregnant mother. In the latter episode, the mother chose to terminate the pregnancy, but fetal tissue tested subsequently by PCR was negative for varicella vaccine virus (147). The children in these episodes had 2, 12, and 30 lesions, respectively. A fourth episode involved transmission from an immunocompetent adolescent who was a resident in an institution for chronically disabled children. The adolescent had >500 lesions after vaccination, and vaccine virus was transmitted to another immunocompetent resident of the institution and to a health-care worker, both of whom had histories of varicella (146). The fifth episode represented a tertiary spread from a healthy sibling contact of a vaccinee with leukemia (148). Rashes for both healthy siblings were mild (i.e., 40 and 11 lesions, respectively), and vaccine virus was isolated from all three case-patients. The third sibling had rash 18 days after the onset of the secondary case-patient and 33 days after rash onset in the vaccinated leukemic child. In addition to these five episodes, one child has been reported to have transmitted vaccine virus from HZ that occurred 5 months after varicella vaccination; 2 weeks later, a mild varicella-like rash from which vaccine varicella virus was isolated occurred in the child's vaccinated brother (156).

Although varicella vaccine is not recommended for children with cellular immune deficiencies, the experience from prelicensure vaccine trials involving children with leukemia is instructive. Data from a study of varicella vaccination in children with leukemia indicated that varicella virus vaccine transmission occurred in 15 (17%) of 88 healthy, susceptible siblings of leukemic vaccine recipients; the rash was mild in

11 (73%) of the 15 infected siblings (148). The risk for transmission was correlated with the number of skin lesions in the immunocompromised vaccine recipients.

These data suggest that healthy, vaccinated persons have a minimal risk for transmitting vaccine virus to their contacts, particularly in the absence of vaccine rash in the vaccine recipient. Vaccine recipients who have a vaccine-related rash, particularly HCP and household contacts of immunocompromised persons, should avoid contact with persons without evidence of immunity who are at high risk for severe complications (see Health-Care Personnel)

Summary of Rationale for Varicella Vaccination

Varicella vaccine is an effective prevention tool for decreasing the burden attributable to varicella disease and its complications in the United States. In the prevaccine era, varicella was a childhood disease with >90% of the 4 million cases, two thirds of approximately 11,000 hospitalizations, and approximately half of 100–150 annual deaths occurring among persons aged <20 years. Single-antigen varicella vaccine is licensed for use among healthy persons aged ≥ 12 months, and the combination MMRV vaccine is licensed for use in healthy children aged 12 months–12 years. Prelicensure and postlicensure studies have demonstrated that 1 dose of single-antigen varicella vaccine is approximately 85% effective in preventing varicella. Breakthrough varicella disease that occurs after vaccination frequently is mild and modified. Varicella vaccine is >95% effective in preventing severe varicella disease. Since implementation of the varicella vaccination program in 1995, varicella incidence, hospitalizations, and deaths have declined substantially. MMRV was licensed on the basis of immunological noninferiority to its vaccine antigenic components. Initial varicella vaccine policy recommendations were for 1 dose of varicella vaccine for children aged 12 months–12 years and 2 doses, 4–8 weeks apart, for persons aged ≥ 13 years. In June 2006, ACIP approved a routine 2-dose recommendation for children. The first dose should be administered at age 12–15 months and the second dose at age 4–6 years.

The rationale for the second dose of varicella vaccine for children is to further decrease varicella disease and its complications in the United States. Despite the successes of the 1-dose vaccination program in children, vaccine effectiveness of 85% has not been sufficient to prevent varicella outbreaks, which, although less than in the prevaccine era, have continued to occur in highly vaccinated school populations. Break-

through varicella is contagious. Studies of the immune response after 1 and 2 doses of varicella vaccine demonstrate a greater-than-tenfold boost in GMTs when measured 6 weeks after the second varicella vaccine dose. A higher proportion (>99%) of children achieve an antibody response of ≥ 5 gpELISA units after the second dose compared with 76%–85% of children after a single dose of varicella vaccine. The second dose of varicella vaccine is expected to provide improved protection to the 15%–20% of children who do not respond adequately to the first dose. Data from a randomized clinical trial conducted postlicensure indicated that vaccine efficacy after 2 doses of single-antigen varicella vaccine in children (98.3%; CI = 97.3%–99.0%) was significantly higher than that after a single dose (94.4%; CI = 92.9%–95.7%). The risk for breakthrough disease was 3.3-fold lower among children who received 2 doses than it was among children who received 1 dose. How this increase in vaccine efficacy (typically higher than observed under field conditions) will translate into vaccine effectiveness under conditions of community use will be an important area of study.

The recommended ages for routine first (at age 12–15 months) and second (at age 4–6 years) doses of varicella vaccine are harmonized with the recommendations for MMR vaccine use and intended to limit the period when children have no varicella antibody. The recommended age for the second dose is supported by the current epidemiology of varicella, with low incidence and few outbreaks among preschool-aged children and higher incidence and more outbreaks among elementary-school-aged children. However, the second dose may be administered at an earlier age, provided that the interval between the first and second doses is 3 months. The recommendation for the minimum interval between doses is made on the basis of the design of the studies evaluating 2 doses among children aged 12 months–12 years. MMRV vaccine may be used to vaccinate children against measles, mumps, rubella, and varicella simultaneously. Because the risk for transmission can be high among students in schools, colleges, and other postsecondary educational institutions, students without evidence of immunity should receive 2 doses of varicella vaccine. All children and adolescents who received 1 dose of varicella vaccine previously should receive a second dose.

Varicella disease is more severe and its complications more frequent among adolescents and adults. The recommendation for vaccination of all adolescents and adults without evidence of immunity will provide protection in these age groups. Because varicella might be more severe in immunocompromised persons who might not be eligible for

vaccination, and because of the risk of VZV transmission in health-care settings, HCP must be vaccinated. Varicella disease during the first two trimesters of pregnancy might infect the fetus and result in congenital varicella syndrome. Therefore, routine antenatal screening for evidence of immunity and postpartum vaccination for those without evidence of immunity now is recommended.

Recommendations for the Use of Varicella Vaccines

Two 0.5-mL doses of varicella vaccine administered subcutaneously are recommended for children aged ≥ 12 months, adolescents, and adults without evidence of immunity. For children aged 12 months–12 years, the recommended minimum interval between the two doses is 3 months. However, if the second dose was administered ≥ 28 days after the first dose, the second dose is considered valid and need not be repeated. For persons aged ≥ 13 years, the recommended minimum interval is 4 weeks. Single-antigen varicella vaccine is approved for use among healthy persons aged ≥ 12 months. Combination MMRV vaccine is approved for use among healthy children aged 12 months–12 years. MMRV vaccine is indicated for simultaneous vaccination against measles, mumps, rubella, and varicella. Whenever any components of the combination vaccine are indicated and the other components are not contraindicated, use of licensed combination vaccines, such as MMRV vaccine, is preferred over separate injection of equivalent component vaccines (157).

Routine Vaccination

Persons Aged 12 Months–12 Years

Preschool-Aged Children

All healthy children should receive their first dose of varicella-containing vaccine routinely at age 12–15 months.

School-Aged Children

A second dose of varicella vaccine is recommended routinely for all children aged 4–6 years (i.e., before entering prekindergarten, kindergarten, or first grade). However, it may be administered at an earlier age provided that the interval between the first and second dose is >3 months.

Because of the risk for transmission of VZV in schools, all children entering school should have received 2 doses of varicella-containing vaccine or have other evidence of immunity to varicella (see Evidence of Immunity).

Persons Aged ≥ 13 Years

Persons aged ≥ 13 years without evidence of varicella immunity should receive two 0.5-mL doses of single-antigen varicella vaccine administered subcutaneously, 4–8 weeks apart. If >8 weeks elapse after the first dose, the second dose may be administered without restarting the schedule. Only single-antigen varicella vaccine may be used for vaccination of persons in this age group. MMRV is not licensed for use among persons aged ≥ 13 years.

School-Aged Children, College Students, and Students in Other Postsecondary Educational Institutions

All students should be assessed for varicella immunity, and those without evidence of immunity should routinely receive 2 doses of single-antigen varicella vaccine 4–8 weeks apart. The risk for transmission of varicella among school-aged children, college students, and students in other postsecondary educational institutions can be high because of high contact rates.

Other Adults

All healthy adults should be assessed for varicella immunity, and those who do not have evidence of immunity should receive 2 doses of single-antigen varicella vaccine 4–8 weeks apart. Adults who might be at increased risk for exposure or transmission and who do not have evidence of immunity should receive special consideration for vaccination, including 1) HCP, 2) household contacts of immunocompromised persons, 3) persons who live or work in environments in which transmission of VZV is likely (e.g., teachers, day-care employees, residents and staff in institutional settings), 4) persons who live or work in environments in which transmission has been reported (e.g., college students, inmates and staff members of correctional institutions, and military personnel), 5) nonpregnant women of childbearing age, 6) adolescents and adults living in households with children, and 7) international travelers.

Second Dose Catch-Up Vaccination

To improve individual protection against varicella and to have a more rapid impact on school outbreaks, second dose catch-up varicella vaccination is recommended for children, adolescents, and adults who previously received 1 dose. The recommended minimum interval between the first dose and the catch-up second dose is 3 months for children aged ≤ 12 years and 4 weeks for persons aged ≥ 13 years. However, the catch-up second dose may be administered at any interval longer than the minimum recommended interval. Catch-up

vaccination may be implemented during routine health-care provider visits and through school- and college-entry requirements.

As part of comprehensive health services for all adolescents, ACIP, AAP, and AAFP recommend a health maintenance visit at age 11–12 years. This visit also should serve as an immunization visit to evaluate vaccination status and administer necessary vaccinations (158). Physicians should use this and other routine visits to ensure that all children without evidence of varicella immunity have received 2 doses of varicella vaccine.

Requirements for Entry to Child Care, School, College, and Other Postsecondary Educational Institutions

Child care and school entry requirements for varicella immunity have been recommended previously (2). In 2005, ACIP recommended expanding the requirements to cover students in all grade levels. Official health agencies should take necessary steps, including developing and enforcing school immunization requirements, to ensure that students at all grade levels (including college) and children in child care centers are protected against varicella and other vaccine-preventable diseases (157).

Prenatal Assessment and Postpartum Vaccination

Prenatal assessment of women for evidence of varicella immunity is recommended. Birth before 1980 is not considered evidence of immunity for pregnant women because of potential severe consequences of varicella infection during pregnancy, including infection of the fetus. Upon completion or termination of their pregnancies, women who do not have evidence of varicella immunity should receive the first dose of vaccine before discharge from the health-care facility. The second dose should be administered 4–8 weeks later, which coincides with the postpartum visit (6–8 weeks after delivery). For women who gave birth, the second dose should be administered at the postpartum visit. Women should be counseled to avoid conception for 1 month after each dose of varicella vaccine. Health-care settings in which completion or termination of pregnancy occurs should use standing orders to ensure the administration of varicella vaccine to women without evidence of immunity.

Special Considerations for Vaccination

Vaccination of HIV-Infected Persons

HIV-infected children with CD4+ T-lymphocyte percentage >15% should be considered for vaccination with the single-antigen varicella vaccine. Varicella vaccine was recommended previously for HIV-infected children in CDC clinical and immunologic categories N1 and A1 with age-specific CD4+ T-lymphocyte percentage $\geq 25\%$ (2). Limited data from a clinical trial in which 2 doses of single-antigen varicella vaccine were administered 3 months apart to 37 HIV-infected children (CDC clinical categories N, A, or B and immunologic category 2 [CD4+ T-lymphocyte percentage $\geq 15\%$ – 24%]) aged 1–8 years indicated that the vaccine was well-tolerated and that >80% of subjects had detectable VZV specific immune response (either antibody or cell immune response or both) at 1 year after immunization (159). These children were no less likely to have an antibody response to the varicella vaccine than were subjects who were less affected immunologically by HIV infection. Because children infected with HIV are at increased risk for morbidity from varicella and HZ (i.e., shingles) compared with healthy children, ACIP recommends that, after weighing potential risks and benefits, single-antigen varicella vaccine should be considered for HIV-infected children with CD4+ T-lymphocyte percentages $\geq 15\%$. Eligible children should receive 2 doses of single-antigen varicella vaccine 3 months apart. Because persons with impaired cellular immunity are potentially at greater risk for complications after vaccination with a live vaccine, these vaccine recipients should be encouraged to return for evaluation if they experience a postvaccination varicella-like rash. Data are not available regarding safety, immunogenicity, or efficacy of MMRV vaccine in HIV-infected children, MMRV vaccine should not be administered as a substitute for the single-antigen varicella vaccine when vaccinating these children. The titer of Oka/Merck VZV is higher in combination MMRV vaccine than in single-antigen varicella vaccine. Recommendations for vaccination of HIV-infected children with measles, mumps, or rubella vaccines have been published previously (160).

Data on use of varicella vaccine in HIV-infected adolescents and adults are lacking. However, on the basis of expert opinion, the safety of varicella vaccine in HIV-infected persons aged >8 years with comparable levels of immune function (CD4+ T-lymphocyte count ≥ 200 cells/ μ L) is likely to be

similar to that of children aged <8 years. Immunogenicity might be lower in older HIV-infected children, adolescents, and adults compared to children aged 1–8 years. However, weighing the risk for severe disease from wild VZV and potential benefit of vaccination, vaccination may be considered (2 doses, administered 3 months apart) for HIV-infected persons with CD4+T-lymphocytes count ≥ 200 cells/ μ L in these age groups. If vaccination of HIV-infected persons results in clinical disease, the use of acyclovir might modify the severity of disease.

Situations in Which Some Degree of Immunodeficiency Might be Present

Persons with impaired humoral immunity may be vaccinated. No data have been published concerning whether persons without evidence of immunity receiving only inhaled, nasal, or topical doses of steroids can be vaccinated safely. However, clinical experience suggests that vaccination is well-tolerated among these persons. Persons without evidence of immunity who are receiving systemic steroids for certain conditions (e.g., asthma) and who are not otherwise immunocompromised may be vaccinated if they are receiving <2 mg/kg of body weight or a total of <20 mg/day of prednisone or its equivalent. Certain experts suggest withholding steroids for 2–3 weeks after vaccination if it can be done safely (1). Data from a Japanese study using the Oka/Biken varicella vaccine (which is not available in the United States but whose immunogenicity and efficacy are similar to those of the varicella vaccine used in the United States) indicated that children taking steroids for nephrosis were vaccinated safely when the steroids were suspended for 1–2 weeks before vaccination, although no serious reactions occurred among children vaccinated when steroid therapy was not suspended (161). Persons who are receiving high doses of systemic steroids (i.e., ≥ 2 mg/kg prednisone) for ≥ 2 weeks may be vaccinated once steroid therapy has been discontinued for ≥ 1 month, in accordance with the general recommendations for the use of live-virus vaccines (157).

Vaccination of leukemic children who are in remission and who do not have evidence of immunity to varicella should be undertaken only with expert guidance and with the availability of antiviral therapy should complications ensue. Patients with leukemia, lymphoma, or other malignancies whose disease is in remission and whose chemotherapy has been terminated for at least 3 months can receive live-virus vaccines (157). When immunizing persons in whom some degree of immunodeficiency might be present, only single-antigen varicella vaccine should be used.

Vaccination of Household Contacts of Immunocompromised Persons

Immunocompromised persons are at high risk for serious varicella infections. Severe disease occurs in approximately 30% of such persons with primary infection. Because varicella vaccine now is recommended for all healthy children and adults without evidence of immunity, household contacts of immunocompromised persons should be vaccinated routinely. Although the risk for exposure to wild VZV for immunocompromised persons now is lower than it was previously, vaccine should be offered to child and adult household contacts without evidence of immunity of immunocompromised persons. Vaccination of household contacts provides protection for immunocompromised persons by decreasing the likelihood that wild-type VZV will be introduced into the household. Vaccination of household contacts of immunocompromised persons theoretically might pose a minimal risk for transmission of vaccine virus to immunocompromised persons, although in one study, no evidence of transmission of vaccine virus was demonstrated after vaccination of 37 healthy siblings of 30 children with malignancy (155). No cases have been documented of transmission of vaccine virus to immunocompromised persons in the postlicensure period in the United States, with >55 million doses of vaccine distributed. Other data indicate that disease caused by vaccine virus in immunocompromised persons is milder than wild-type disease and can be treated with acyclovir (148,159). The benefits of vaccinating susceptible household contacts of immunocompromised persons outweigh the extremely low potential risk for transmission of vaccine virus to immunocompromised contacts. Vaccine recipients in whom vaccine-related rash occurs, particularly HCP and household contacts of immunocompromised persons, should avoid contact with susceptible persons who are at high risk for severe complications. If a susceptible, immunocompromised person is inadvertently exposed to a person who has a vaccine-related rash, postexposure prophylaxis with VZIG is not needed because disease associated with this type of virus is expected to be mild.

Nursing Mothers

Postpartum vaccination of women without evidence of immunity need not be delayed because of breastfeeding. Women who have received varicella vaccination postpartum may continue to breastfeed. The majority of live vaccines are not associated with virus secretion in breast milk (157). A study involving 12 women who received single-antigen varicella vaccine while breastfeeding indicated no evidence of VZV DNA

either in 217 breast milk samples collected or in infants tested after both vaccine doses (162). No infants seroconverted. Another study did not detect varicella gene sequences in the postvaccination breast milk samples (163). Therefore, single-antigen varicella vaccine should be administered to nursing mothers without evidence of immunity. Combination MMRV vaccine is not licensed for use among persons aged ≥ 13 years.

Health-Care Personnel

Nosocomial transmission of VZV is well-recognized (131,164–173), and guidelines for the prevention of nosocomial VZV infection and for infection control in HCP have been published (174,175). Sources of nosocomial exposure have included patients, hospital staff, and visitors (e.g., the children of hospital employees) who are infected with varicella or HZ. In hospitals, airborne transmission of VZV has been demonstrated when varicella has occurred in susceptible persons who had no direct contact with the index case-patient (176–180).

To prevent disease and nosocomial spread of VZV, health-care institutions should ensure that all HCP have evidence of immunity to varicella. Birth before 1980 is not considered evidence of immunity for HCP because of the possibility of nosocomial transmission to high-risk patients. In health-care institutions, serologic screening before vaccination of personnel who have a negative or uncertain history of varicella and who are unvaccinated is likely to be cost effective. Institutions may elect to test all HCP regardless of disease history because a small proportion of persons with a positive history of disease might be susceptible.

Routine testing for varicella immunity after 2 doses of vaccine is not recommended for the management of vaccinated HCP. Available commercial assays are not sensitive enough to detect antibody after vaccination in all instances. Sensitive tests have indicated that 99% of adults develop antibodies after the second dose. However, seroconversion does not always result in full protection against disease, and no data regarding correlates of protection are available for adults.

HCP who have received 2 doses of vaccine and who are exposed to VZV should be monitored daily during days 10–21 after exposure through the employee health program or by an infection control nurse to determine clinical status (i.e., daily screen for fever, skin lesions, and systemic symptoms). Persons with varicella might be infectious up to 2 days before rash onset. In addition, HCP should be instructed to report fever, headache, or other constitutional symptoms and any atypical skin lesions immediately. HCP should be placed on sick leave immediately if symptoms occur. Health-care institutions should establish protocols and recommendations for

screening and vaccinating HCP and for management of HCP after exposures in the work place.

HCP who have received 1 dose of vaccine and who are exposed to VZV should receive the second dose with single-antigen varicella vaccine within 3–5 days after exposure to rash (provided 4 weeks have elapsed after the first dose). After vaccination, management is similar to that of 2-dose vaccine recipients.

Unvaccinated HCP who have no other evidence of immunity who are exposed to VZV are potentially infective from days 10–21 after exposure and should be furloughed during this period. They should receive postexposure vaccination as soon as possible. Vaccination within 3–5 days of exposure to rash might modify the disease if infection occurred. Vaccination >5 days postexposure still is indicated because it induces protection against subsequent exposures (if the current exposure did not cause infection).

The risk for transmission of vaccine virus from vaccine recipients in whom varicella-like rash occurs after vaccination is low and has been documented after exposures in households and long-term care facilities (140,146–148). No cases have been documented after vaccination of HCP. The benefits of vaccinating HCP without evidence of immunity outweigh this extremely low potential risk. As a safeguard, institutions should consider precautions for personnel in whom rash occurs after vaccination. HCP in whom a vaccine-related rash occurs should avoid contact with persons without evidence of immunity who are at risk for severe disease and complications until all lesions resolve (i.e., are crusted over or fade away) or no new lesions appear within a 24-hour period.

Varicella IgG Antibody Testing

The tests most widely used to detect varicella IgG antibody after natural varicella infection among HCP are latex agglutination (LA) and ELISA. A commercially available LA test using latex particles coated with VZV glycoprotein antigens can be completed in 15 minutes and does not require special equipment (181). The sensitivity and specificity of the LA test are comparable to those of FAMA in detecting antibody response after natural varicella infection. The LA test generally is more sensitive than commercial ELISAs. The LA test has detected antibody for up to 11 years after varicella vaccination (182). However, for the purpose of screening HCP for varicella susceptibility, a less sensitive and more specific commercial ELISA should be considered. A recent report indicated that the LA test can produce false-positive results, particularly when only a single concentration of serum is evaluated (183); this led to documented cases of false-positive results in HCP who consequently remained unvaccinated and subsequently contracted varicella.

Vaccination for Outbreak Control

Varicella vaccination is recommended for outbreak control. Persons who do not have adequate evidence of immunity should receive their first or second dose as appropriate. Additionally, in outbreaks among preschool-aged children, 2-dose vaccination is recommended for optimal protection, and children vaccinated with 1 dose should receive their second dose provided 3 months have elapsed since the first dose. State and local health departments may advise exposed persons who do not have evidence of immunity to contact their health-care providers for vaccination, or they may offer vaccination through the health department or school (or other institutions) vaccination clinics. Although outbreak control efforts optimally should be implemented as soon as an outbreak is identified, vaccination should be offered even if the outbreak is identified late. Varicella outbreaks in certain settings (e.g., child care facilities, schools, or institutions) can last as long as 4–5 months. Thus, offering vaccine during an outbreak might provide protection to persons not yet exposed and shorten the duration of the outbreak (184). Persons receiving either their first or second dose as part of the outbreak control program may be readmitted to school immediately. Those vaccinated with the first dose as part of outbreak control measures should be scheduled for the second dose as age appropriate. Persons who are unvaccinated and without other evidence of immunity who do not receive vaccine should be excluded from institutions in which the outbreak is occurring until 21 days after the onset of rash in the last case of varicella. In addition, for school-aged persons covered by the 2-dose school vaccination requirements, exclusion during an outbreak is recommended for those vaccine recipients who had received the first dose before the outbreak but not the second as part of the outbreak control program. Persons at increased risk for severe varicella who have contraindications to vaccination should receive VZIG within 96 hours of exposure.

Contraindications

General

Adequate treatment provisions for anaphylactic reactions, including epinephrine injection (1:1000), should be available for immediate use should an anaphylactic reaction occur. Before administering a vaccine, health-care providers should obtain the vaccine recipient's vaccination history and determine whether the individual had any previous reactions to any vaccine including VARIVAX, ProQuad or any measles, mumps, or rubella containing vaccines.

Allergy to Vaccine Components

The administration of live varicella-containing vaccines rarely results in hypersensitivity. The information in the package insert should be reviewed carefully before vaccine is administered. Vaccination is contraindicated for persons who have a history of anaphylactic reaction to any component of the vaccine, including gelatin. Single-antigen varicella vaccine does not contain preservatives or egg protein; these substances have caused hypersensitive reactions to other vaccines. For the combination MMRV vaccine, live measles and live mumps vaccines are produced in chick embryo culture. However, among persons who are allergic to eggs, the risk for serious allergic reactions after administration of measles- or mumps-containing vaccines is low. Because skin testing with vaccine is not predictive of allergic reaction to vaccination, skin testing is not required before administering combination MMRV vaccine to persons who are allergic to eggs (160). The majority of anaphylactic reactions to measles- and mumps-containing vaccines are associated not with hypersensitivity to egg antigens but with other vaccine components. Neither single-antigen varicella nor combination MMRV vaccines should be administered to persons who have a history of anaphylactic reaction to neomycin. However, neomycin allergy usually is manifested as a contact dermatitis, which is a delayed-type immune response rather than anaphylaxis. For persons who experience such a response, the adverse reaction, if any, would appear as an erythematous, pruritic nodule or papule present 48–96 hours after vaccination. A history of contact dermatitis to neomycin is not a contraindication to receiving varicella vaccines.

Altered Immunity

Single-antigen varicella and combination MMRV vaccines are not licensed for use in persons who have any malignant condition, including blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. Combination MMRV vaccine should not be administered to persons with primary or acquired immunodeficiency, including immunosuppression associated with AIDS or other clinical manifestations of HIV infections, cellular immunodeficiencies, hypogammaglobulinemia, and dysgammaglobulinemia. Combination MMRV vaccine should not be administered as a substitute for the component vaccines when vaccinating HIV-infected children.

Varicella vaccines should not be administered to persons who have a family history of congenital or hereditary immunodeficiency in first-degree relatives (e.g., parents and siblings) unless the immune competence of the potential vaccine

recipient has been clinically substantiated or verified by a laboratory.

Varicella vaccines should not be administered to persons receiving high-dose systemic immunosuppressive therapy, including persons on oral steroids ≥ 2 mg/kg of body weight or a total of ≥ 20 mg/day of prednisone or equivalent for persons who weigh > 10 kg, when administered for ≥ 2 weeks. Such persons are more susceptible to infections than healthy persons. Administration of varicella vaccines can result in a more extensive vaccine-associated rash or disseminated disease in persons receiving immunosuppressive doses of corticosteroids (185). This contraindication does not apply to persons who are receiving inhaled, nasal, or topical corticosteroids or low-dose corticosteroids as are used commonly for asthma prophylaxis or for corticosteroid-replacement therapy (see Situations in Which Some Degree of Immunodeficiency Might Be Present).

Pregnancy

Because the effects of the varicella virus vaccine on the fetus are unknown, pregnant women should not be vaccinated. Nonpregnant women who are vaccinated should avoid becoming pregnant for 1 month after each injection. For persons without evidence of immunity, having a pregnant household member is not a contraindication to vaccination.

If a pregnant woman is vaccinated or becomes pregnant within 1 month of vaccination, she should be counseled about potential effects on the fetus. Wild-type varicella poses a low risk to the fetus (see Prenatal and Perinatal Exposure). Because the virulence of the attenuated virus used in the vaccine is less than that of the wild-type virus, the risk to the fetus, if any, should be even lower. In 1995, Merck and Co., Inc., in collaboration with CDC, established the VARIVAX Pregnancy Registry to monitor the maternal-fetal outcomes of pregnant women who were inadvertently administered varicella vaccine 3 months before or at any time during pregnancy (to report, call: 1-800-986-8999) (186). During the first 10 years of the pregnancy registry no cases of congenital varicella syndrome or birth defects compatible with congenital varicella syndrome have been documented (187,188). Among 131 live-born infants of prospectively reported seronegative women (82 of whom were born to mothers vaccinated during the highest risk period [i.e., the first or second trimester of pregnancy]), no birth defects consistent with congenital varicella syndrome have been documented (prevalence rate = 0; CI = 0–6.7%), and three major birth defects were reported (prevalence rate = 2.3%; CI = 0.5%–6.7%). The rate of occurrence of major birth defects from prospective reports

in the registry was similar to the rate reported in the general U.S. population (3.2%), and the defects indicated no specific pattern or target organ. Although the study results do not exclude the possibility of risk for women who received inadvertent varicella vaccination before or during pregnancy, the potential risk, if any, is low.

Precautions

Illness

Vaccination of persons who have acute severe illness, including untreated, active tuberculosis, should be postponed until recovery. The decision to delay vaccination depends on the severity of symptoms and on the etiology of the disease. No data are available regarding whether either single-antigen varicella or combination MMRV vaccines exacerbate tuberculosis. Live attenuated measles, mumps, and rubella virus vaccines administered individually might result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin test is to be performed, it should be administered either any time before, simultaneously with, or at least 4–6 weeks after combination MMRV vaccine. However, tuberculin skin testing is not a prerequisite for vaccination with single-antigen varicella or combination MMRV vaccines.

Varicella vaccines may be administered to children without evidence of immunity who have mild illnesses, with or without low-grade fever (e.g., diarrhea or upper-respiratory infection) (189). Physicians should be alert to the vaccine-associated temperature elevations that might occur predominantly in the second week after vaccination, especially with combination MMRV vaccine. Studies suggest that failure to vaccinate children with minor illnesses can impede vaccination efforts (190).

Thrombocytopenia

Thrombocytopenia is not a contraindication for single-antigen varicella vaccine. No clinical data are available regarding the development or worsening of thrombocytopenia in persons vaccinated with combination MMRV vaccine. Cases of thrombocytopenia have been reported after MMR vaccine and after varicella vaccination. Postmarketing experience with live MMR vaccine indicates that persons with thrombocytopenia might develop more severe thrombocytopenia after vaccination. For vaccination of thrombocytopenic children with combination MMRV vaccine, health-care providers should refer to the ACIP recommendations on MMR vaccination (160).

Recent Administration of Blood, Plasma, or Immune Globulin

Although passively acquired antibody is known to interfere with response to measles and rubella vaccines (191), the effect of the administration of immune globulin (IG) on the response to varicella virus vaccine is unknown. The duration of interference with the response to measles vaccination is dose-related and ranges from 3–11 months. Because of the potential inhibition of the response to varicella vaccination by passively transferred antibodies, varicella vaccines should not be administered for the same intervals as measles vaccine (3–11 months, depending on the dosage) after administration of blood (except washed red blood cells), plasma, or IG. Suggested intervals between administration of antibody-containing products for different indications and varicella vaccine have been published previously (157). In addition, persons who received a varicella vaccine should not be administered an antibody-containing product for 2 weeks after vaccination unless the benefits exceed those of vaccination. In such cases, the vaccine recipient should either be revaccinated or tested for immunity at the appropriate intervals, depending on the dose received, and then revaccinated if seronegative.

Use of Salicylates

No adverse events associated with the use of salicylates after varicella vaccination have been reported; however, the vaccine manufacturer recommends that vaccine recipients avoid using salicylates for 6 weeks after receiving varicella vaccines because of the association between aspirin use and Reye syndrome after varicella. Vaccination with subsequent close monitoring should be considered for children who have rheumatoid arthritis or other conditions requiring therapeutic aspirin. The risk for serious complications associated with aspirin is likely to be greater in children in whom natural varicella develops than it is in children who receive the vaccine containing attenuated VZV. No association has been documented between Reye syndrome and analgesics or antipyretics that do not contain salicylic acid.

Postexposure Prophylaxis

Healthy Persons

Prelicensure data from the United States and Japan on varicella exposures in children from household, hospital, and community settings indicate that single-antigen varicella vaccine

is effective in preventing illness or modifying varicella severity if administered to unvaccinated children within 3 days, and possibly up to 5 days, of exposure to rash (78,101,192). Vaccination within 3 days of exposure to rash was $\geq 90\%$ effective in preventing varicella whereas vaccination within 5 days of exposure to rash was approximately 70% effective in preventing varicella and 100% effective in modifying severe disease (101,192). Limited postlicensure studies also have demonstrated that varicella vaccine is highly effective in either preventing or modifying disease if administered within 3 days of exposure (193,194). Varicella vaccine is recommended for postexposure administration for unvaccinated persons without other evidence of immunity. If exposure to VZV does not cause infection, postexposure vaccination should induce protection against subsequent exposures. If the exposure results in infection, no evidence indicates that administration of single-antigen varicella vaccine during the presymptomatic or prodromal stage of illness increases the risk for vaccine-associated adverse events. No data are available regarding the potential benefit of administering a second dose to 1-dose vaccine recipients after exposure. However, administration of a second dose should be considered for persons who have previously received 1 dose to bring them up-to-date. Studies on postexposure use of varicella vaccine have been conducted exclusively in children. A higher proportion of adults do not respond to the first dose of varicella vaccine. Nevertheless, postexposure vaccination should be offered to adults without evidence of immunity. Although postexposure use of varicella vaccine has potential applications in hospital settings, vaccination is recommended routinely for all HCP without evidence of immunity and is the preferred method for preventing varicella in health-care settings (195). Preferably, HCP should be vaccinated when they begin employment. No data are available on the use of combination MMRV vaccine for postexposure prophylaxis.

Persons Without Evidence of Immunity Who Have Contraindications for Vaccination and Who Are at Risk for Severe Disease and Complications

Studies conducted in 1969 indicated that clinical varicella was prevented in nonimmune, healthy children by the administration of zoster immune globulin (ZIG) (prepared from patients recovering from HZ) within 72 hours of exposure (196). ZIG also lowered attack rates among immunocompromised persons if administered no later than 96 hours after exposure (196). VZIG (prepared from plasma

obtained from healthy, volunteer blood donors identified by routine screening to have high antibody titers to VZV) became available in 1978. Both serologic and clinical evaluations have demonstrated that the product is equivalent to ZIG in preventing or modifying clinical illness in non-immune, immunocompromised persons who are exposed to varicella (197,198). In a study of immunocompromised children who were administered VZIG within 96 hours of exposure, approximately one in five exposures resulted in clinical varicella, and one in 20 resulted in subclinical disease (198). The severity of clinical varicella (evaluated by percentage of patients with >100 lesions or complications) was lower than expected on the basis of historic controls.

The VZIG product currently used in the United States, VariZIG™ (Cangene Corporation, Winnipeg, Canada), is available under an Investigational New Drug Application Expanded Access protocol (available at <http://www.fda.gov/cber/infosheets/mphvzig020806.htm>). A request for licensure in the United States might be submitted to FDA in the future. VariZIG is a lyophilized presentation which, when properly reconstituted, is approximately a 5% solution of IgG that can be administered intramuscularly (199). VariZIG can be obtained 24 hours a day from the sole authorized U.S. distributor (FFF Enterprises, Temecula, California) at 1-800-843-7477 or online at <http://www.fffenterprises.com>.

Administration of VZIG

VZIG provides maximum benefit when administered as soon as possible after exposure, but it might be effective if administered as late as 96 hours after exposure. The effectiveness of VZIG when administered >96 hours after initial exposure has not been evaluated. The duration of protection provided after administration of VZIG is unknown, but protection should last at least one half-life of the IG (i.e., approximately 3 weeks). Susceptible persons at high risk for whom varicella vaccination is contraindicated and who are again exposed ≥ 3 weeks after receiving a dose of VZIG should receive another full dose of VZIG. Patients receiving monthly high-dose immune globulin intravenous (IGIV) (≥ 400 mg/kg) are likely to be protected and probably do not require VZIG if the last dose of IGIV was administered <3 weeks before exposure (200). VZIG has not been proven to be useful in treating clinical varicella or HZ or in preventing disseminated zoster and is not recommended for such use. VZIG might extend the incubation period of the virus from 10–21 days to ≥ 28 days. This should be taken into account after exposures when VZIG is administered.

Dosage

VariZIG is supplied in 125-U vials. The recommended dose is 125 units/10 kg of body weight, up to a maximum of 625 units (five vials). The minimum dose is 125 U. The human IgG content is 60–200 mg per 125 units dose of VariZIG.

Indications for the Use of VZIG for Postexposure Prophylaxis

The decision to administer VZIG depends on three factors: 1) whether the patient lacks evidence of immunity, 2) whether the exposure is likely to result in infection, and 3) whether the patient is at greater risk for complications than the general population.

Both healthy and immunocompromised children and adults who have verified positive histories of varicella (except for bone-marrow transplant recipients) may be considered immune (see Evidence of Immunity). The association between positive histories of varicella in bone-marrow donors and susceptibility to varicella in recipients after transplants has not been studied adequately. Thus, persons who receive bone-marrow transplants should be considered nonimmune, regardless of previous history of varicella disease or varicella vaccination in themselves or in their donors. Bone-marrow recipients in whom varicella or HZ develops after transplantation should subsequently be considered immune.

VZIG is not indicated for persons who received 2 doses of varicella vaccine and became immunocompromised as a result of disease or treatment later in life. These persons should be monitored closely; if disease occurs, treatment with acyclovir should be instituted at the earliest signs or symptoms. For patients without evidence of immunity and on steroid therapy doses ≥ 2 mg/kg of body weight or a total of 20 mg/day of prednisone or equivalent, VariZIG is indicated.

Types of Exposure

Certain types of exposure can place persons without evidence of immunity at risk for varicella. Direct contact exposure is defined as face-to-face contact with an infectious person while indoors. The duration of face-to-face contact that warrants administration of VZIG is not certain. However, the contact should not be transient. Certain experts suggest a contact of >5 minutes as constituting significant exposure for this purpose, whereas others define close contact as >1 hour (200). Substantial exposure for hospital contacts consists of sharing the same hospital room with an infectious patient or direct, face-to-face contact with an infectious person (e.g., HCP). Brief contacts with an infectious person (e.g., contact with

x-ray technicians or housekeeping personnel) are less likely than more prolonged contacts to result in VZV transmission.

Persons with continuous exposure to household members who have varicella or disseminated HZ are at greatest risk for infection. Varicella occurs in approximately 85% (range: 65%–100%) of susceptible household contacts exposed to VZV. Localized HZ is much less infectious than varicella or disseminated HZ (52). Transmission from localized HZ is more likely after close contact, such as in household settings. Physicians may consider recommending postexposure prophylaxis with VZIG in such circumstances. After household exposure to varicella, attack rates among immunocompromised children who were administered VZIG were up to 60% (197). No comparative data are available for immunocompromised children without evidence of immunity who were not administered VZIG. However, the incidence of severe disease (defined as >100 skin lesions) was less than that predicted from the natural history of disease in normal children (27% and 87%, respectively), and the incidence of pneumonia was less than that described in children with neoplasm (6% and 25%, respectively) (201). The risk for varicella after close contact (e.g., contact with playmates) or hospital exposure is estimated to be approximately 20% of the risk occurring from household exposure.

The attack rate in healthy neonates who were exposed in utero within 7 days of delivery and who received VZIG after birth was 62%, which does not differ substantially from rates reported for neonates who were similarly exposed but not treated with VZIG (49). However, the occurrence of complications and fatal outcomes was substantially lower for neonates who were treated with VZIG than for those who were not.

In a study of pregnant women without immunity to VZV who were exposed to varicella and administered VZIG, the infection rate was 30%. This is substantially lower than the expected rate of >70% in unimmunized women exposed to varicella (199,202).

Recommendations for the Use of VZIG

The following patient groups are at risk for severe disease and complications from varicella and should receive VZIG:

Immunocompromised patients. VZIG is used primarily for passive immunization of immunocompromised persons without evidence of immunity after direct exposure to varicella or disseminated HZ patients, including persons who 1) have primary and acquired immune-deficiency disorders, 2) have neoplastic diseases, and 3) are receiving immunosuppressive treatment. Patients receiving monthly high-dose IGIV (≥ 400 mg/kg) are likely to be protected and probably do not

require VZIG if the last dose of IGIV was administered ≤ 3 weeks before exposure (200).

Neonates whose mothers have signs and symptoms of varicella around the time of delivery. VZIG is indicated for neonates whose mothers have signs and symptoms of varicella from 5 days before to 2 days after delivery. VZIG is not necessary for neonates whose mothers have signs and symptoms of varicella more than 5 days before delivery, because those infants should be protected from severe varicella by transplacentally acquired maternal antibody. No evidence suggests that infants born to mothers in whom varicella occurs >48 hours after delivery are at increased risk for serious complications (e.g., pneumonia or death).

Premature neonates exposed postnatally. Transmission of varicella in the hospital nursery is rare because the majority of neonates are protected by maternal antibody. Premature infants who have substantial postnatal exposure should be evaluated on an individual basis. The risk for complications of postnatally acquired varicella in premature infants is unknown. However, because the immune system of premature infants is not fully developed, administration of VZIG to premature infants born at ≥ 28 weeks of gestation who are exposed during the neonatal period and whose mothers do not have evidence of immunity is indicated. Premature infants born at <28 weeks of gestation or who weigh $\leq 1,000$ g at birth and were exposed during the neonatal period should receive VZIG regardless of maternal immunity because such infants might not have acquired maternal antibody. The majority of premature infants born at ≥ 28 weeks of gestation to immune mothers have enough acquired maternal antibody to protect them from severe disease and complications. Although infants are at higher risk than older children for serious and fatal complications, the risk for healthy, full-term infants who have varicella after postnatal exposure is substantially less than that for infants whose mothers were infected 5 days before to 2 days after delivery. VZIG is not recommended for healthy, full-term infants who are exposed postnatally, even if their mothers have no history of varicella infection.

Pregnant women. Because pregnant women might be at higher risk for severe varicella and complications (37,42,203), VZIG should be strongly considered for pregnant women without evidence of immunity who have been exposed. Administration of VZIG to these women has not been found to prevent viremia, fetal infection, congenital varicella syndrome, or neonatal varicella. Thus, the primary indication for VZIG in pregnant women is to prevent complications of varicella in the mother rather than to protect the fetus. Neonates born to mothers who have signs and symptoms of

varicella from 5 days before to 2 days after delivery should receive VZIG, regardless of whether the mother received VZIG.

Interval Between Administration of VZIG and Varicella Vaccine

Any patient who receives VZIG to prevent varicella should receive varicella vaccine subsequently, provided the vaccine is not contraindicated. Varicella vaccination should be delayed until 5 months after VZIG administration. Varicella vaccine is not needed if the patient has varicella after administration of VZIG.

Antiviral Therapy

Because VZIG might prolong the incubation period by ≥ 1 week, any patient who receives VZIG should be observed closely for signs or symptoms of varicella for 28 days after exposure. Antiviral therapy should be instituted immediately if signs or symptoms of varicella disease occur. The route and duration of antiviral therapy should be determined by specific host factors, extent of infection, and initial response to therapy. Information regarding how to obtain VariZIG is available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a5.htm> (204).

Acknowledgments

Gregory Wallace, MD, Mary Mulholland, MA, Tony Richardson, MS, MPH, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, assisted in the writing of the section on vaccine storage and handling. Fangjun Zhou, PhD, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, performed the economic analysis. Jessica Leung, MPH, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC, helped with the graphs, tables, and references.

References

1. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1996;45 (No. RR-11).
2. CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1999;48 (No. RR-6).
3. Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? *Pediatrics* 2006;117:e1070–7.
4. CDC. Outbreak of varicella among vaccinated children—Michigan, 2003. *MMWR* 2004;53:389–92.
5. Tugwell BD, Lee LE, Gillette H, Lorber EM, Hedberg K, Cieslak PR. Chickenpox outbreak in a highly vaccinated school population. *Pediatrics* 2004;113:455–9.
6. Parker AA, Reynolds M, Leung J, et al. Challenges to implementing second dose varicella vaccination during an outbreak in the absence of a routine two-dose vaccination requirement—Maine, 2006. *J Infect Dis* (suppl). In press 2007.
7. LaRussa P. Clinical manifestations of varicella. In: Arvin A, Gershon A, eds. *Varicella-zoster virus*. Cambridge, UK: Cambridge University Press; 2000:206–19.
8. Wharton M. The epidemiology of varicella-zoster virus infections. *Infect Dis Clin N Amer* 1996;10:571–81.
9. CDC. Evaluation of varicella reporting to the National Notifiable Disease Surveillance System—United States, 1972–1997. *MMWR* 1999;48:55–8.
10. Finger R, Hughes JP, Meade BJ, et al. Age-specific incidence of chickenpox. *Pub Health Rep* 1994;190:750–5.
11. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. *J Pediatr* 1997;130:759–65.
12. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol* 2003;70 Suppl 1:S111–8.
13. Longfield JN, Winn RE, Gibson RL, Juchau SV, Hoffman PV. Varicella outbreak in army recruits from Puerto Rico. Varicella susceptibility in a population from the tropics. *Arch Intern Med* 1990;150:970–3.
14. CDC. Varicella outbreaks among Mexican adults—Alabama, 2000. *MMWR* 2000;49:735–6.
15. Garnett GP, Cox MJ, Bundy DAP, Didier JM, St. Catherine J. The age of infection with varicella-zoster virus in St. Lucia, West Indies. *Epidemiol Infect* 1993;110:361–72.
16. Lolekha S, Tanthiphabha W, Sornchai P, et al. Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. *Am J Trop Med Hyg* 2001;64:131–6.
17. Mandal BK, Mukherjee PP, Murphy C, Mukherjee R, Naik T. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. *J Infect Dis* 1998;178(Suppl):S52–4.
18. Seward J, Galil K, Wharton M. Epidemiology of varicella. In: Arvin A, Gershon A, eds. *Varicella-zoster virus*. Cambridge, UK: Cambridge University Press; 2000:187–205.
19. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. *Trop Med Int Health* 1998;3:886–90.
20. Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. *Pediatr Infect Dis J* 2002;21:931–5.
21. Ratner AJ. Varicella-related hospitalizations in the vaccine era. *Pediatr Infect Dis J* 2002;21:927–30.
22. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. *Pediatrics* 2004;114:786–92.
23. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. *JAMA* 2005;294:797–802.
24. Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. *New Engl J Med* 1985;313:849–57.
25. Remington RL, Rowley D, McGee H, et al. Decreasing trends in Reye's syndrome and aspirin use in Michigan 1979 to 1984. *Pediatrics* 1986;77:93–8.
26. Belay ED, Bresee JS, Holman RC, et al. Reye's syndrome in the United States from 1981 through 1997. *New Engl J Med* 1999;340:1377–82.

27. Meyer P, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. *J Infect Dis* 2000;182:383–90.
28. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. *N Engl J Med* 2005;352:450–8.
29. Enders G, Miller E. Varicella and herpes zoster in pregnancy and newborn. In: Arvin A, Gershon A, eds. *Varicella-zoster virus*. Cambridge, UK: Cambridge University Press; 2000:317–47.
30. Luman ET, Ching PLYH, Jumaan AO, Seward JF. Uptake of varicella vaccination among young children in the United States: a success story in eliminating racial and ethnic disparities. *Pediatrics* 2006;117:999–1008.
31. CDC. National, state, and urban area vaccination coverage among children aged 19–35 months—United States, 2005. *MMWR* 2006;55:988–93.
32. CDC. Decline in annual incidence of varicella—selected states, 1990–2001. *MMWR* 2003;52:884–5.
33. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. *JAMA* 2002;287:606–11.
34. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites—United States, 1995–2005. *J Infect Dis (Suppl)*. In press 2007.
35. Galil K, Pletcher MJ, Wallace BJ, et al. Tracking varicella deaths: accuracy and completeness of death certificates and hospital discharge records, New York State, 1989–1995. *Am J Public Health* 2002;92:1248–50.
36. Gershon AA, Raker R, Steinberg S, Topf-Olstein B, Drusin LM. Antibody to varicella-zoster virus in parturient women and their offspring during the first year of life. *Pediatrics* 1976;58:692–6.
37. Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. *N Engl J Med* 1986;314:1542–6.
38. Brunell PA, Kotchmar GS. Zoster in infancy: failure to maintain virus latency following intrauterine infection. *J Pediatr* 1981;98:71–3.
39. Brunell PA. Varicella in pregnancy, the fetus, and the newborn: problems in management. *J Infect Dis* 1992;166(Suppl 1):S42–7.
40. Laforet EG, Lynch C. Multiple congenital defects following maternal varicella. *N Engl J Med* 1947;236:534–7.
41. Enders G. Varicella-zoster virus infection in pregnancy. *Prog Med Virol* 1984;29:166–96.
42. Balducci J, Rodis JF, Rosengren S, Vintzileos AM, Spivey G, Vosseller C. Pregnancy outcome following first-trimester varicella infection. *Obstet Gynecol* 1992;79:5–6.
43. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. *Lancet* 1994;343:1548–51.
44. Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. *N Engl J Med* 1994;330:901–5.
45. Meyers JD. Congenital varicella in term infants: risks reconsidered. *J Infect Dis* 1974;129:215–7.
46. Brunell PA. Fetal and neonatal varicella-zoster infections. *Semin Perinatol* 1983;7:47–56.
47. Tan MP, Koren G. Chickenpox in pregnancy: revisited. *Reprod Toxicol* 2006;21:e410–20.
48. Bai PV, John TJ. Congenital skin ulcers following varicella in late pregnancy. *J Pediatr* 1979. 94:65–7.
49. Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. *Lancet* 1989;2:371–3.
50. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. *Proc R Soc Med* 1965;58:9–20.
51. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. *Epidemiol Infect* 2001;127:305–14.
52. Seiler HE. A study of herpes zoster particularly in its relationship to chickenpox. *J Hyg (Lond)* 1949;47:253–62.
53. Takayama N, Takayama M, Takita J. Herpes zoster in healthy children immunized with varicella vaccine. *Pediatr Infect Dis J* 2000;19:169–70.
54. Hardy I, Gershon AA, Steinberg S, et al. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. *N Engl J Med* 1991;325:1545–50.
55. Lawrence R, Gershon AA, Holzman R, Steinberg SP, NIAID Varicella Vaccine Collaborative Study Group. The risk of zoster after varicella vaccination in children with leukemia. *N Engl J Med* 1988;318:543–8.
56. Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. *Pediatr Infect Dis J* 1999;18:1041–6.
57. White CJ. Clinical trials of varicella vaccine in healthy children. *Infect Dis Clin N Amer* 1996;10:595–608.
58. Gershon AA. Varicella vaccine: rare serious problems—but the benefits still outweigh the risks. *J Infect Dis* 2003;188:945–7.
59. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modeling the impact of immunization on the epidemiology of varicella-zoster virus. *Epidemiol Infect* 2000;125:651–69.
60. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. *J Infect Dis* 2005;191:2002–7.
61. Insinga RP, Itzler RE, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. *J Gen Intern Med* 2005;20:748–53.
62. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997–2002. *Epidemiol Infect* 2005;133:245–53.
63. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. *BMC Public Health* 2005;5:68.
64. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. *Arch Intern Med* 1995;155:1605–9.
65. Civen RH, Maupin TJ, Xiao H, Seward J, Jumaan AO, Mascola L. A population-based study of herpes zoster in children and adolescents post-varicella vaccine licensure. Presented at the 41st Annual Meeting of the Infectious Disease Society of America, San Diego, California; October 9–12, 2003.
66. Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children—a collaborative study. *J Pediatr* 1982;101:622–5.
67. Balfour HH Jr. Intravenous acyclovir therapy for varicella in immunocompromised children. *J Pediatr* 1984;104:134–6.

68. Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. *J Infect Dis* 1988;157:309–13.
69. Balfour HH, Kelly JM, Suarez CS, et al. Acyclovir treatment of varicella in otherwise healthy children. *J Pediatr* 1990;116:633–9.
70. Dunkle LM, Arvin AM, Whitley RJ, et al. A controlled trial of acyclovir for chickenpox in normal children. *N Engl J Med* 1991;325:1539–44.
71. Balfour HH Jr, Rotbart HA, Feldman S, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. *J Pediatr* 1992;120:627–33.
72. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC III. Treatment of adult varicella with oral acyclovir. *Ann Intern Med* 1992;117:358–63.
73. Feder HM Jr. Treatment of adult chickenpox with oral acyclovir. *Arch Intern Med* 1990;150:2061–5.
74. Committee on Infectious Diseases, American Academy of Pediatrics. The use of oral acyclovir in otherwise healthy children with varicella. *Pediatrics* 1993;91:674–6.
75. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the International Acyclovir Pregnancy Registry, 1984–1999. *Birth Defects Research* 2004 (Pt A)70:201–7.
76. Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. *Am J Med* 1988;85 (Suppl 2A):84–9.
77. Anonymous Famciclovir for herpes zoster. *The Medical Letter on Drugs and Therapeutics* 1994;36:97–8.
78. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. *Lancet* 1974;2:1288–90.
79. Merck & Co., Inc. VARIVAX [Package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 1995.
80. Merck & Co., Inc. ProQuad (measles, mumps, rubella, and varicella [Oka/Merck] virus vaccine live)[Package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2005.
81. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. *Pediatrics* 1991;87:604–10.
82. Michalik DE, LaRussa PS, Steinberg SP, Wright P, Edwards K, Gershon AA. Primary immune failure after one dose of varicella vaccine are likely a cause of breakthrough infections in healthy vaccinated children. In: 44th Infectious Disease Society of America Annual Meeting, Toronto, Ontario, Canada; October 11–14, 2006.
83. Chan ISF, Li S, Matthews H, et al. Use of statistical models for evaluating antibody response as a correlate of protection against varicella. *Stat Med* 2002;21:3411–30.
84. Li S, Chan ISF, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. *Pediatr Infect Dis J* 2002;21:337–42.
85. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. *Pediatr Infect Dis J* 2004;23:132–7.
86. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. *Pediatrics* 1997;100:761–6.
87. Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. *Pediatrics* 1985;75:667–71.
88. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. *Pediatrics* 1994;94:524–6.
89. Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. *J Infect Dis* 1995;172:217–9.
90. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. *Pediatr Infect Dis J* 2005;24:665–9.
91. Reisinger KS, Hoffman Brown ML, Xu J, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. *Pediatrics* 2006;117:265–72.
92. Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adults. *Vaccine* 1995;13:967–72.
93. Gershon AA, Steinberg SP, LaRussa P, et al. NIAID -Varicella-Vaccine-Collaborative -Study-Group. Immunization of healthy adults with live attenuated varicella vaccine. *J Infect Dis* 1988;158:132–7.
94. Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus vaccination among health care workers. *Inf Cont Hosp Epidemiol* 2001;22:279–83.
95. Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. *Clin Infect Dis* 2002;34:774–9.
96. Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. *J Infect Dis* 1998;177:1701–4.
97. Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. *Clin Infect Dis* 1995;20:316–9.
98. Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus in children and adults immunized with live attenuated varicella vaccine. *J Infect Dis* 1995;171:13–7.
99. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. *Pediatr Infect Dis J* 1992;11:19–23.
100. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (VARIVAX®) in children and adults. *Vaccine* 1997;15:61–4.
101. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. *Pediatrics* 1986;78 (Suppl):748–56.
102. Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. *J Pediatr* 1995;127:518–25.
103. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. *N Engl J Med* 1984;310:1409–15.
104. Gershon AA, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA, eds. *Vaccines*. 4th ed. Philadelphia: WB Saunders Company; 2004.
105. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. *Vaccine* 1991;9:643–7.
106. Seward JE, Marin M, Vasquez M. Varicella vaccine effectiveness in the United States vaccination program: a review. *J Infect Dis* (Suppl). In press 2007.

107. Buchholz U, Moolenaar R, Peterson C, Mascola L. Varicella outbreaks after vaccine licensure: should they make you chicken? *Pediatrics* 1999;104:561–3.
108. Dworkin MS, Jennings CE, Roth-Thomas J, et al. An outbreak of varicella among children attending preschool and elementary school in Illinois. *Clin Infect Dis* 2002;35:102–4.
109. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. *JAMA* 1997;278:1495–9.
110. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. *J Infect Dis* 2002;186:102–5.
111. Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002–2003. *Pediatrics* 2005;115:900–5.
112. CDC. Varicella outbreak among vaccinated children—Nebraska, 2004. *MMWR* 2006;55:749–52.
113. Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002–2003. *Pediatrics* 2005;115:1488–93.
114. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. *N Engl J Med* 2002;347:1909–15.
115. Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. *J Infect Dis* 2004;190:477–83.
116. Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day-care setting. *Pediatr Infect Dis J* 1999; 18:1047–50.
117. Vázquez MD, LaRussa PS, Gershon AA, Steinberg SP, Freudigman KF, Shapiro E. The effectiveness of the varicella vaccine in clinical practice. *N Engl J Med* 2001;344:955–60.
118. Vázquez MD, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. *JAMA* 2004;291:851–5.
119. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. *JAMA* 2004;292:704–8.
120. Bernstein HH, Rothstein EP, Pennridge Pediatric Associates, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. *Pediatrics* 1993;92:833–7.
121. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. *Pediatrics* 1993;91:17–22.
122. Arbeter AM, Starr SE, Preblud SR, et al. Varicella vaccine trials in healthy children: a summary of comparative and follow-up studies. *Am J Dis Child* 1984;138:434–8.
123. Vessey SJR, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. *J Pediatr* 2001;139:297–304.
124. Chaves SS, Zhang J, Civen R, et al. Varicella disease in vaccinated persons: clinical and epidemiologic characteristics, 1997–2005. *J Infect Dis (Suppl)*. In press 2007.
125. Verstraeten T, Jumaan AO, Mullooly JP, et al. Vaccine Safety Datalink Research Group. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. *Pediatrics* 2003;112:e98–103.
126. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. *N Engl J Med* 2007;356:1121–9.
127. Black S, Ray P, Shinefield H, Saddier P and Nikas A. Lack of association of age at varicella vaccination with risk of breakthrough disease within Northern California Kaiser Permanente. *J Infect Dis*. In press 2007.
128. Peterson CL, Vugia DJ, Meyers HB, et al. Risk factors for invasive group A streptococcal infections in children with varicella: a case-control study. *Pediatr Infect Dis J* 1996;15:151–6.
129. Silk HJ, Guay-Woodford L, Perez-Atayde AR, Geha RS, Broff MD. Fatal varicella in steroid-dependent asthma. *J Allergy Clin Immunol* 1988;81:47–51.
130. Dowell SF, Bresee JS. Severe varicella associated with steroid use. *Pediatrics* 1993;92:223–8.
131. Alter SJ, Hammond JA, McVey CJ, Myers MG. Susceptibility to varicella-zoster virus among adults at high risk for exposure. *Am J Infect Control* 1986;7:448–51.
132. Struewing JP, Hyams KC, Tueller JE, Gray GC. The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. *Am J Public Health* 1993;83:1717–20.
133. McKinney WP, Horowitz MM, Battiola RJ. Susceptibility of hospital-based health care personnel to varicella-zoster virus infections. *Am J Infect Control* 1989;17:26–30.
134. Perella D, Fiks A, Spain CV, et al. Validity of reported varicella history as a marker for varicella-zoster virus immunity [Poster]. 2005 Pediatric Academic Societies Annual Meeting, Washington, DC; May 14–17, 2005.
135. Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. *J Pediatr* 1989;114:37–44.
136. Black SB, Cimino CO, Hansen, J, et al. Immunogenicity and safety of measles-mumps-rubella, varicella and *Haemophilus influenzae* type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. *Pediatr Infect Dis J* 2006;25:306–11.
137. Shinefield H, Black S, Thear M, et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined *Haemophilus influenzae* type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. *Pediatr Infect Dis J* 2006;25:287–92.
138. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for U.S. Children. *JAMA* 1994; 271:375–81.
139. Ngai AL, Stahele BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. *Pediatr Infect Dis J* 1996;15:49–54.
140. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. *Vaccine* 2001;19:916–23.
141. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. *JAMA* 2000;284:1271–9.
142. Guess HA, Broughton DD, Melton LJ, 3rd, Kurland LT. Population-based studies of varicella complications. *Pediatrics* 1986;78 (4 Pt 2):723–7.
143. Ghaffar F, Carrick K, Rogers BB, Margraf LR, Krisher K, Ramilo O. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. *Pediatr Infect Dis J* 2000;19:764–6.

144. Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. *J Infect Dis* 2003;188:948–53.
145. Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. *J Infect Dis* 2003;188:954–9.
146. Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. Secondary transmission of varicella vaccine virus in a chronic care facility for children. *J Pediatr* 2006;148:842–4.
147. Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12 month old child to his pregnant mother. *J Pediatr* 1997;131:151–4.
148. Tsolia M, Gershon AP, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. *J Pediatr* 1990;116:184–9.
149. Lee SY, Komp DM, Andiman W. Thrombocytopenic purpura following varicella-zoster vaccination. *Am J Pediatr Hematol Oncol* 1986;8:78–80.
150. Sunaga Y, Hikima A, Ostuka T, Morikawa A. Acute cerebellar ataxia with abnormal MRI lesions after varicella vaccination. *Pediatr Neurol* 1995;13:340–2.
151. Wirrell E, Hill MD, Jadavji T, Kirton A, Barlow K. Stroke after varicella vaccination. *J Pediatr* 2004;145:845–7.
152. Singer S, Johnson CE, Mohr R, Holowecky C. Urticaria following varicella vaccine associated with gelatin allergy. *Vaccine* 1999;17:327–9.
153. Bronstein DE, Cotliar J, Votava-Smith JK, et al. Recurrent papular urticaria after varicella immunization in a fifteen-month-old girl. *Pediatr Infect Dis J* 2005;24:269–70.
154. Guess HA, Broughton DD, Melton LJ, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. *Pediatrics* 1985;76:512–7.
155. Diaz PS, Au D, Smith S. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. *Pediatrics* 1991;87:166–70.
156. Brunell PA, Argaw T. Chickenpox attributable to a vaccine virus contracted from a vaccinee with zoster. *Pediatrics* 2000;106:e28.
157. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;55(No. RR-15).
158. CDC. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. *MMWR* 1996;45(No. RR-13).
159. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B; Pediatric AIDS Clinical Trials Group 265 Team. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. *J Infect Dis* 2006;194:247–55.
160. CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1998;47(No. RR-8).
161. Takahashi M, Kamiya H, Baba K, Ozaki T, Horiuchi K. Clinical experience with Oka live varicella vaccine in Japan. *Postgrad Med J* 1985;61(Suppl):61–7.
162. Bohlke K, Galil K, Jackson LA, et al. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? *Obstet Gynecol* 2003;102:970–7.
163. Dolbear GL, Moffat J, Falkner C, Wojtowycz M. A pilot study: is attenuated varicella virus present in breast milk after postpartum immunization? *Obstet Gynecol* 2003;101(Suppl):S47.
164. Meyers JD, MacQuarrie MB, Merigan TC, Jennison MH. Nosocomial varicella. Part 1: outbreak in oncology patients at a children's hospital. *West J Med* 1979;130:196–9.
165. Morens DM, Bregman DJ, West CM, et al. An outbreak of varicella-zoster virus infection among cancer patients. *Ann Intern Med* 1980;93:414–9.
166. Baltimore RS. Nosocomial infections in the pediatric intensive care unit. *Yale J Biol Med* 1984;57:185–97.
167. Gustafson TL, Shehab Z, Brunell PA. Outbreak of varicella in a newborn intensive care nursery. *Am J Dis Child* 1984;138:548–50.
168. Hyams PJ, Stuewe MC, Heitzer V. Herpes zoster causing varicella (chickenpox) in hospital employees: cost of a casual attitude. *Am J Infect Control* 1984;12:2–5.
169. Shehab ZM, Brunell PA. Susceptibility of hospital personnel to varicella-zoster virus. *J Infect Dis* 1984;150:786.
170. Weitekamp MR, Schan P, Aber RC. An algorithm for the control of nosocomial varicella-zoster virus infection. *Am J Infect Control* 1985;13:193–8.
171. Krasinski K, Holzman RS, LaCouture R, Florman A. Hospital experience with varicella-zoster virus. *Infect Control* 1986;7:312–6.
172. Haiduven-Griffiths D, Fecko H. Varicella in hospital personnel: a challenge for the infection control practitioner. *Am J Infect Control* 1987;15:207–11.
173. Weber DJ, Rutala WA, Parham C. Impact and costs of varicella prevention in a university hospital. *Am J Public Health* 1988;78:19–23.
174. Garner JS. Guidelines for isolation precautions in hospitals. *Infect Cont Hosp Epid* 1996;17:54–80.
175. Bolyard EA, Tablan, OC, Williams WW. Et al. Guideline for infection control in healthcare personnel, 1998: Hospital Infection Control Practices Advisory Committee. *Infect Cont Hosp Epid* 1999;19:407–63.
176. Asano Y, Iwayama S, Miyata T, et al. Spread of varicella in hospitalized children having no direct contact with an indicator zoster case and its prevention by a live vaccine. *Biken J* 1980;23:157–61.
177. Leclair JM, Zaia JA, Levine MJ, Congdon RG, Goldmann DA. Airborne transmission of chickenpox in a hospital. *N Engl J Med* 1980;302:450–3.
178. Gustafson TL, Lavelly GB, Brawner ER, Hutcheson RH, Wright PF, Schaffner W. An outbreak of airborne nosocomial varicella. *Pediatrics* 1982;70:550–6.
179. Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. *J Infect Dis* 1988;158:238–41.
180. Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. Detection of varicella-zoster virus DNA in air samples from hospital room. *J Infect Dis* 1994;169:91–4.
181. Steinberg SP, Gershon AA. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. *J Clin Microbiol* 1991;29:1527–9.

182. Gershon AA, LaRussa PS, Steinberg SP. Detection of antibodies to varicella zoster virus using a latex agglutination assay. *Clin Diag Virol* 1994;2:271–7.
183. Behrman A, Schmid DS, Crivaro A, Watson B. A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers. *Infect Control Hosp Epidemiol* 2003;24:202–6.
184. Hall S, Galil K, Seward J and Watson B. The use of school-based vaccination clinics to control varicella outbreaks in two schools. *Pediatrics* 2000; 105:e17–20.
185. Lydick E, Kuter BJ, Zajac BA, Guess HA, The National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Association of steroid therapy with vaccine-associated rashes in children with acute lymphocytic leukaemia who received Oka/Merck varicella vaccine. *Vaccine* 1989;7:549–53.
186. CDC. Establishment of VARIVAX Pregnancy Registry. *MMWR* 1996;45:239.
187. Shields KE, Galil K, Seward J, Sharrar RG, Cordero JF, Slater E. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. *Obstet Gynecol* 2001;98:14–9.
188. Wilson E, Goss MA, Marin M, et al. Varicella vaccine exposure during pregnancy: data from ten years of the pregnancy registry. *J Infect Dis*. In press 2007.
189. Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella (MMRV) vaccine of children with upper respiratory tract infection. *Pediatrics* 1994;94:514–6.
190. Farizo KM, Stehr-Green PA, Markowitz LE, Patriarca PA. Vaccination levels and missed opportunities for measles vaccination: a record audit in a public pediatric clinic. *Pediatrics* 1992;89:589–92.
191. Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. *J Pediatr* 1993;122:204–11.
192. Asano Y, Nakayama H, Yazaki T, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. *Pediatrics* 1977;59:3–7.
193. Salzman MB and Garcia C. Post exposure varicella vaccination in siblings of children with active varicella. *Pediatr Infect Dis J* 1998;17:256–7.
194. Watson B, Seward J, Yang A, et al. Postexposure effectiveness of varicella vaccine. *Pediatrics* 2000;105:84–8.
195. CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR* 1997;46(No. RR-18).
196. CDC. Varicella zoster immune globulin for the prevention of chickenpox. *MMWR* 1984;33:84–90, 95–100.
197. Zaia J, Levin MJ, Preblud SK, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. *J Infect Dis* 1983;147:737–43.
198. Levin MJ, Nelson WL, Preblud SR, Zaia JA. Clinical trials with varicella-zoster immunoglobulins, in Movell A, Nydegger, eds. *Clinical use of intravenous immunoglobulins*. London, UK: Academic Press Inc., Ltd; 1986:255–67.
199. Cangene Corporation. VariZIG [Package insert]. Winnipeg, Canada: Cangene Corporation; 2005. Available at http://www.cangene.com/pdf/VariZIG_Monograph.English.pdf.
200. American Academy of Pediatrics. Varicella-zoster infections. In: Pickering LK, ed. *Red book: 2006 report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:711–25.
201. Zaia JA, Levin MJ, Preblud SR. The status of passive immunization for Herpesvirus infections. In: Alving BM, Finlayson JS, eds. *Immunoglobulins: characteristics and use of intravenous preparations*. Bethesda, MD: US Department of Health and Human Services; 1980 (DHHS publication no. [FDA] 80-9005):111–21.
202. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC III. Treatment of adult varicella with oral acyclovir. *Ann Intern Med* 1992;117:358–63.
203. Haris RE, Rhoades ER. Varicella pneumonia complicating pregnancy: report of a case and review of the literature. *Obstet Gynecol* 1965;25:734–40.
204. CDC. A new product (VariZIG™) for postexposure prophylaxis of varicella available under an Investigational New Drug application expanded access protocol. *MMWR* 2006;55:209–10.

Appendix

Summary of Recommendations for Varicella Vaccination

Routine Childhood Schedule

- Routine childhood vaccination should be 2 doses.
- Preschool-aged children should receive the first dose of varicella vaccine at age 12–15 months.
- School-aged children should receive the second dose at age 4–6 years (may be administered earlier provided ≥ 3 months have elapsed after the first dose)

Persons Aged ≥ 13 Years

- Persons aged ≥ 13 years should receive 2 doses of vaccine, doses (4–8 weeks apart).
- All adolescents and adults without evidence of immunity should be vaccinated.
- Because of their increased risk for transmission to persons at high risk for severe disease or their increased risk of exposure, vaccination is especially important for persons without evidence of immunity in the following groups:
 - persons who have close contact with persons at high risk for serious complications (e.g., health-care personnel and household contacts of immunocompromised persons);
 - persons who live or work in environments in which transmission of varicella zoster virus is likely (e.g., teachers, child-care workers, and residents and staff in institutional settings);
 - persons who live and work in environments in which transmission has been reported (e.g., college students, inmates and staff members of correctional institutions, military personnel);
 - nonpregnant women of childbearing age;
 - adolescents and adults living in households with children; and
 - international travelers.

Prenatal Assessment and Postpartum Vaccination

Prenatal assessment of women for evidence of varicella immunity is recommended. Upon completion or termination of pregnancy, women who do not have evidence of varicella immunity should be vaccinated.

Vaccination of HIV-Infected Persons

Vaccination should be considered for HIV-infected children with age-specific CD4+ T-lymphocyte percentage $\geq 15\%$ and may be considered for adolescents and adults in with CD4+ T-lymphocyte count ≥ 200 cells/ μ L.

Outbreak Control

- 2-dose vaccination policy

Postexposure Prophylaxis

- Recommended within 3–5 days

Requirements for Entry to Child Care, School, College, and Other Postsecondary Educational Institutions

All states should require that students at all grade levels (including college) and those in child care centers receive varicella vaccine unless they have other evidence of immunity of varicella.

Evidence of Immunity to Varicella

Evidence of immunity to varicella includes any of the following:

- documentation of age-appropriate vaccination with a varicella vaccine:
 - preschool-aged children (i.e., aged ≥ 12 months): 1 dose
 - school-aged children, adolescents, and adults: 2 doses*
- laboratory evidence of immunity[†] or laboratory confirmation of disease;
- birth in the United States before 1980[§];
- diagnosis or verification of a history of varicella disease by a health-care provider[¶]; or
- diagnosis or verification of a history of herpes zoster by a health-care provider.

* For children who received their first dose at age < 13 years and for whom the interval between the 2 doses was ≥ 28 days, the second dose is considered valid.

[†] Commercial assays can be used to assess disease-induced immunity, but they lack sensitivity to always detect vaccine-induced immunity (i.e., they might yield false-negative results).

[§] For health-care personnel, pregnant women, and immunocompromised persons, birth before 1980 should not be considered evidence of immunity.

[¶] Verification of history or diagnosis of typical disease can be provided by any health-care provider (e.g., school or occupational clinic nurse, nurse practitioner, physician assistant, or physician). For persons reporting a history of, or reporting with, atypical or mild cases, assessment by a physician or their designee is recommended, and one of the following should be sought: 1) an epidemiologic link to a typical varicella case or to a laboratory-confirmed case or 2) evidence of laboratory confirmation if it was performed at the time of acute disease. When such documentation is lacking, persons should not be considered as having a valid history of disease because other diseases might mimic mild atypical varicella.

Advisory Committee on Immunization Practices Varicella Working Group

Chair: Judith R. Campbell, MD, Houston, Texas

Members: Ann M. Arvin, MD, Stanford, California; David W. Kimberlin, MD, Birmingham, Alabama; James L. Hadler, MD, Hartford, Connecticut; Barbara Watson, MB ChB, Philadelphia, Pennsylvania; Penina Haber, MPH, Atlanta, Georgia; William Atkinson, MD, Atlanta, Georgia; Anne A. Gershon, MD, New York, New York; Tracy Lieu, MD, Boston, Massachusetts; Teresa Thornton, Des Moines, Iowa; Myron J. Levin, Denver, Colorado; John F. Modlin, MD, Lebanon, New Hampshire; Dale L. Morse, MD, Albany, New York; Reginald Finger, MD, Colorado Springs, Colorado; Dalya Guris, MD, Atlanta, Georgia; Mona Marin, MD, Atlanta, Georgia; Sandra S. Chaves, MD, Atlanta, Georgia; Paul Gargiullo, PhD, Atlanta, Georgia; John W. Glasser, PhD, Atlanta, Georgia; Rafael Harpaz, MD, Atlanta, Georgia; Gregory Wallace, MD, Atlanta, Georgia; Jane F. Seward, MBBS, Atlanta, Georgia; Scott Schmid, PhD, Atlanta, Georgia; Philip LaRussa, MD, New York, New York; Angela Calugar, MD, Atlanta, Georgia; H. Cody Meissner, MD, Boston, Massachusetts; Philip R. Krause, MD, Bethesda, Maryland; Keith Powell, MD, Akron, Ohio; Gustavo H. Dayan, MD, Atlanta, Georgia.

Advisory Committee on Immunization Practices

Membership List, June 2006

Chairman: Jon Abramson, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

Executive Secretary: Larry Pickering, MD, CDC, Atlanta, Georgia.

Members: Ban Mishu Allos, MD, Vanderbilt University School of Medicine, Nashville, Tennessee; Judith Campbell, MD, Baylor College of Medicine, Houston, Texas; Robert Beck, JD, Consumer Representative, Palmyra, Virginia; Reginald Finger, MD, Focus on the Family, Colorado Springs, Colorado; Janet Gilsdorf, MD, University of Michigan, Ann Arbor, Michigan; Harry Hull, MD, Minnesota Department of Health, St. Paul, Minnesota; Tracy Lieu, MD, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts; Edgar Marcuse, MD, Children's Hospital and Regional Medical Center, Seattle, Washington; Dale Morse, MD, New York State Department of Health, Albany, New York; Julia Morita, MD, Chicago Department of Public Health, Chicago, Illinois; Gregory Poland, MD, Mayo Medical School, Rochester, Minnesota; Patricia Stinchfield, MSN, Children's Hospitals and Clinics of Minnesota, St. Paul, Minnesota; John J. Treanor, MD, University of Rochester, Rochester, New York; Robin Womeodu, MD, University Hospital, Memphis, Tennessee.

Ex-Officio Members: James E. Cheek, MD, Indian Health Services, Albuquerque, New Mexico; Wayne Hachey, DO, Department of Defense, Falls Church, Virginia; Geoffrey S. Evans, MD, Health Resources and Services Administration, Rockville, Maryland; Bruce Gellin, MD, National Vaccine Program Office, Washington, DC; Linda Murphy, Centers for Medicare and Medicaid Services, Baltimore, Maryland; George T. Curlin, MD, National Institutes of Health, Bethesda, Maryland; Kristin Lee Nichol, MD, Department of Veterans Affairs, Minneapolis, Minnesota.

Liaison Representatives: American Academy of Family Physicians, Jonathan Temte, MD, Madison, Wisconsin, and Doug Campos-Outcalt, MD, Phoenix, Arizona; American Academy of Pediatrics, Keith Powell, MD, Akron, Ohio, and Carol Baker, MD, Houston, Texas; America's Health Insurance Plans, Andrea Gelzer, MD, Hartford, Connecticut; American College Health Association, James C. Turner, MD, Charlottesville, Virginia; American College of Obstetricians and Gynecologists, Stanley Gall, MD, Louisville, Kentucky; American College of Physicians, Kathleen M. Neuzil, MD, Seattle, Washington; American Medical Association, Litjen Tan, PhD, Chicago, Illinois; American Pharmacists Association, Stephan L. Foster, PharmD, Memphis, Tennessee; Association of Teachers of Preventive Medicine, W. Paul McKinney, MD, Louisville, Kentucky; Biotechnology Industry Organization, Clement Lewin, PhD, Cambridge, Massachusetts; Canadian National Advisory Committee on Immunization, Monica Naus, MD, Vancouver, British Columbia; Healthcare Infection Control Practices Advisory Committee, Steve Gordon, MD, Cleveland, Ohio; Infectious Diseases Society of America, Samuel L. Katz, MD, Durham, North Carolina; London Department of Health, David Salisbury, MD, London, United Kingdom; National Association of County and City Health Officials, Nancy Bennett, MD, Rochester, New York, and Jeffrey S. Duchin, MD, Seattle, Washington; National Coalition for Adult Immunization, David A. Neumann, PhD, Alexandria, Virginia; National Foundation for Infectious Diseases, William Schaffner, MD, Nashville, Tennessee; National Immunization Council and Child Health Program, Romeo S. Rodriguez, Mexico City, Mexico; National Medical Association, Patricia Whitley-Williams, MD, New Brunswick, New Jersey; National Vaccine Advisory Committee, Gary Freed, MD, Swiftwater, Pennsylvania, and Peter Paradiso, PhD, Collegeville, Pennsylvania; Society for Adolescent Medicine, Amy B. Middleman, MD, Houston, Texas; Pharmaceutical Research and Manufacturers of America, Damian A. Araga, Swiftwater, Pennsylvania.

Advisory Committee on Immunization Practices

Membership List, June 2005

Chairman: Myron J. Levin, MD, University of Colorado Health Sciences Center, Denver, Colorado.

Executive Secretary: Larry K. Pickering, MD, Senior Advisor to the Director, National Immunization Program, CDC, Atlanta, Georgia.

Members: Jon S. Abramson, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Ban Mishu Allos, MD, Vanderbilt University School of Medicine, Nashville, Tennessee; Guthrie S. Birkhead, MD, New York State Department of Health, Albany, New York; Judith Campbell, MD, Baylor College of Medicine, Houston, Texas; Reginald Finger, MD, Focus on the Family, Colorado Springs, Colorado; Janet R. Gilsdorf, MD, University of Michigan, Ann Arbor, Michigan; Tracy Lieu, MD, Harvard Pilgrim Healthcare and Harvard Medical School, Boston, Massachusetts; Edgar K. Marcuse, MD, Children's Hospital and Regional Medical Center, Seattle, Washington; Julie Morita, MD, Chicago Department of Public Health, Chicago, Illinois; Gregory A. Poland, MD, Mayo Medical School, Rochester, Minnesota; John B. Salamone, National Italian American Foundation, Washington, D.C.; Patricia, Stinchfield, MS, Children's Hospitals and Clinics, St. Paul, Minnesota; John J. Treanor, MD, University of Rochester School of Medicine and Dentistry, Rochester, New York; and Robin J. Womeodu, MD, University of Tennessee Health Sciences Center, Memphis, Tennessee.

Ex-Officio Members: James E. Cheek, MD, Indian Health Service, Albuquerque, New Mexico; Wayne Hachey, DO, Department of Defense, Falls Church, Virginia; Geoffrey S. Evans, MD, Health Resources and Services Administration, Rockville, Maryland; Bruce Gellin, MD, National Vaccine Program Office, Washington, DC; Linda Murphy, Centers for Medicare and Medicaid Services, Baltimore, Maryland; George T. Curlin, MD, National Institutes of Health, Bethesda, Maryland; Norman Baylor, PhD, Office of Vaccines Research Review, Rockville, Maryland; Kristin Lee Nichol, MD, Department of Veterans Affairs, Minneapolis, Minnesota.

Liaison Representatives: Jonathan Temte, MD, Madison, Wisconsin, Richard D. Clover, MD, Louisville, Kentucky, American Academy of Family Physicians; Margaret Rennels, MD, Baltimore, Maryland, Carol Baker, MD, Houston, Texas, American Academy of Pediatrics; Andrea Gelzer, MD, Hartford, Connecticut, America's Health Insurance Plans; James C. Turner, MD, Charlottesville, Virginia, American College Health Association; Stanley Gall, MD, Louisville, Kentucky, American College of Obstetricians and Gynecologists; Kathleen M. Neuzil, MD, Seattle, Washington, American College of Physicians; Litjen Tan, PhD, Chicago, Illinois, American Medical Association; Stephan L. Foster, PharmD, Memphis, Tennessee, American Pharmacists Association; W. Paul McKinney, MD, Louisville, Kentucky, Association of Teachers of Preventive Medicine; Clement Lewin, PhD, Orange, Connecticut, Biotechnology Industry Organization; Monika Naus, MD, Vancouver, British Columbia, Canada, Canadian National Advisory Committee on Immunization; Steve Gordon, MD, Cleveland, Ohio, Healthcare Infection Control Practices Advisory Committee, Samuel L. Katz, MD, Durham, North Carolina, and William Schaffner, MD, Nashville, Tennessee, Infectious Diseases Society of America; David M. Salisbury, MD, London, United Kingdom, London Department of Health; Nancy Bennett, MD, Rochester, New York, National Association of County and City Health Officials; David A. Neumann, PhD, Alexandria, Virginia, National Coalition for Adult Immunization; Romeo Rodriguez, Mexico City, Mexico, National Immunization Council and Child Health Program; Dennis A. Brooks, MD, Baltimore, Maryland, National Medical Association; Charles Helms, MD, Iowa City, Iowa, National Vaccine Advisory Committee; Amy B. Middleman, MD, Houston, Texas, Society for Adolescent Medicine; Damian A. Braga, MBA, Swiftwater, Pennsylvania, Peter Paradiso, PhD, Collegeville, Pennsylvania, Pharmaceutical Research and Manufacturers of America.



Morbidity and Mortality Weekly Report

Recommendations and Reports
June 22, 2007 / Vol. 56 / RR-4

Continuing Education Activity Sponsored by CDC

Prevention of Varicella

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

EXPIRATION — June 22, 2009

You must complete and return the response form electronically or by mail by June 22, 2009, to receive continuing education credit. If you answer all of the questions, you will receive an award letter for 2.25 hours Continuing Medical Education (CME) credit; 0.02 Continuing Education Units (CEUs); 2.25 contact hours Continuing Nursing Education (CNE) credit; 2.0 contact hours

Certified Health Education Specialist (CHES) credit; or 0.2 hours Continuing Pharmacy Education (CPE) credit. If you return the form electronically, you will receive educational credit immediately. If you mail the form, you will receive educational credit in approximately 30 days. No fees are charged for participating in this continuing education activity.

INSTRUCTIONS

By Internet

1. Read this *MMWR* (Vol. 56, RR-4), which contains the correct answers to the questions beginning on the next page.
2. Go to the *MMWR* Continuing Education Internet site at <http://www.cdc.gov/mmwr/cme/conted.html>.
3. Select which exam you want to take and select whether you want to register for CME, CEU, CNE, CHES, or CPE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
6. Submit your answers no later than **June 22, 2009**.
7. Immediately print your Certificate of Completion for your records.

By Mail or Fax

1. Read this *MMWR* (Vol. 56, RR-4), which contains the correct answers to the questions beginning on the next page.
2. Complete all registration information on the response form, including your name, mailing address, phone number, and e-mail address.
3. Indicate whether you are registering for CME, CEU, CNE, CHES, or CPE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
5. Sign and date the response form or a photocopy of the form and send no later than **June 22, 2009**, to
Fax: 404-498-2388
Mail: MMWR CE Credit
CCHIS, Centers for Disease Control and Prevention
1600 Clifton Rd, N.E., MS E-90
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.

ACCREDITATION

Continuing Medical Education (CME). CDC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CDC designates this educational activity for a maximum of 2.25 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Continuing Education Unit (CEU). CDC has been reviewed and approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET) 8405 Greensboro Drive, Suite 800, McLean, VA 22102. The CDC has awarded (0.02) CEU's to participants who successfully complete this program.

Continuing Nursing Education (CNE). CDC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. CDC will award 2.25 contact hour(s) in CNE credit.

Certified Health Education Specialist (CHES). CDC is a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is a designated event for CHESs to receive 2.0 category I contact hour(s) in health education. The CDC provider number is GA0082.

Continuing Pharmacy Education (CPE). CDC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.2 contact hour(s) in pharmacy education. The universal program number is 387-000-07-018-H01.

Goal and Objectives

This report revises, updates, and replaces the 1996 and 1999 ACIP statements of CDC's Advisory Committee on Immunization Practices for prevention of varicella in the United States. The goal of this report is to improve the health status of the U.S. population by providing recommendations on the use of varicella vaccines for prevention of varicella disease. Upon completion of this educational activity, the reader should be able to 1) describe the epidemiology of varicella in the United States, 2) identify recommendations for varicella vaccination in the United States, and 3) describe the characteristics of the currently licensed varicella vaccines.

To receive continuing education credit, please answer all of the following questions.

1. **Which of the following are recommendations for the use of varicella vaccines? (Indicate all that apply.)**
 - A. Children aged 12 months–12 years should routinely receive 2 doses of varicella vaccine at age 12–15 months and at age 4–6 years, respectively.
 - B. Children can receive the second dose earlier than age 4–6 years, provided ≥ 3 months have elapsed after the first dose.
 - C. Persons aged ≥ 13 years and without evidence of immunity should receive 2 doses of vaccine 4–8 weeks apart.
 - D. A catch-up second dose is recommended for children, adolescents, and adults who had received 1 dose.
 - E. All of the above.
2. **Among persons aged ≥ 13 years without evidence of immunity, which groups should receive special consideration for vaccination? (Indicate all that apply.)**
 - A. Students in postsecondary educational institutions.
 - B. Health-care providers.
 - C. Household contacts of immunocompromised persons.
 - D. Persons at high risk for exposure or transmission.
 - E. Women of child bearing age.
 - F. International travelers.
 - G. All of the above.
3. **Which of the following is not a criterion for evidence of immunity to varicella?**
 - A. Documentation of age-appropriate vaccination
 - B. Birth in the United States before 1980.
 - C. A diagnosis of varicella by a health-care provider.
 - D. A self- or parental report of varicella disease.
 - E. A verification of history of varicella disease by a health-care provider.
4. **Which of the following are characteristics of breakthrough varicella? (Indicate all that apply.)**
 - A. Breakthrough varicella cases usually are mild.
 - B. Breakthrough varicella cases are infectious.
 - C. In 25%–30% of cases, breakthrough varicella has features similar to those in unvaccinated persons.
 - D. A and C are correct.
 - E. A, B, and C are correct.
5. **Are breakthrough varicella cases contagious?**
 - A. Yes.
 - B. No.
 - C. Not known.
6. **Varicella vaccines....**
 - A. must be refrigerated.
 - B. are contraindicated in pregnancy.
 - C. are inactivated vaccines.
 - D. may be administered starting at age 9 months.
 - E. contain thimerosal.
7. **In clinical trials, the second dose varicella vaccine...**
 - A. had an estimated 10-year efficacy of 98%.
 - B. reduced the risk of breakthrough varicella by 3.3-fold compared with 1 dose.
 - C. induced a titer ≥ 5 units gpELISA at 6 weeks postvaccination in 99% of vaccine recipients.
 - D. A and B are correct.
 - E. A, B, and C are correct.
8. **In the prevaccine era, varicella resulted in how many hospitalizations and deaths annually?**
 - A. Very few hospitalizations or deaths.
 - B. Approximately 5,000 hospitalizations and 50 deaths.
 - C. Approximately 11,000 hospitalizations and 100–150 deaths.
 - D. Approximately 20,000 hospitalizations and 200 deaths.
9. **Which of the following statements are characteristics of the epidemiology of varicella in the United States 10 years after the implementation of the 1-dose vaccination program as documented in the active surveillance sites? (Indicate all that apply.)**
 - A. Varicella incidence declined 90% compared with the prevaccine era.
 - B. Decline in incidence was observed in all age groups, even those not targeted for vaccination.
 - C. Outbreaks continue to occur.
 - D. More than 50% of reported cases of varicella occur among vaccinated persons.
 - E. All of the above.
10. **Combination measles, mumps, rubella, and varicella (MMRV) vaccine is licensed for use among all healthy persons aged ≥ 12 months.**
 - A. True.
 - B. False.
11. **Which best describes your professional activities?**
 - A. Physician.
 - B. Nurse.
 - C. Health educator.
 - D. Office staff.
 - E. Other.
12. **I plan to use these recommendations as the basis for ... (Indicate all that apply.)**
 - A. health education materials.
 - B. insurance reimbursement policies.
 - C. local practice guidelines.
 - D. public policy.
 - E. other.
13. **Overall, the length of the journal report was...**
 - A. much too long.
 - B. a little too long.
 - C. just right.
 - D. a little too short.
 - E. much too short.

- 14. After reading this report, I am confident I can describe the epidemiology of varicella in the United States.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.
- 15. After reading this report, I am confident I can identify recommendations for varicella vaccination in the United States.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.
- 16. After reading this report, I am confident I can describe the characteristics of currently licensed varicella vaccines.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.
- 17. The learning outcomes (objectives) were relevant to the goals of this report.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.

- 18. The instructional strategies used in this report (text, tables, figures, boxes, and appendix) helped me learn the material.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.
- 19. The content was appropriate given the stated objectives of the report.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.
- 20. The content expert(s) demonstrated expertise in the subject matter.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.
- 21. Overall, the quality of the journal report was excellent.
 - A. Strongly agree.
 - B. Agree.
 - C. Undecided.
 - D. Disagree.
 - E. Strongly disagree.

(Continued on pg CE-4)

**MMWR Response Form for Continuing Education Credit
June 22, 2007/Vol. 56/No. RR-4**
**Prevention of Varicella
Recommendations of the Advisory Committee
on Immunization Practices (ACIP)**

To receive continuing education credit, you must
 1. provide your contact information (please print or type);
 2. indicate your choice of CME, CME for nonphysicians, CEU, CNE, CHES, or CPE credit;
 3. answer all of the test questions;
 4. sign and date this form or a photocopy;
 5. submit your answer form by June 22, 2009.
 Failure to complete these items can result in a delay or rejection of your application for continuing education credit.

Detach or photocopy.

Check One
 CME Credit
 CME for nonphysicians Credit
 CEU Credit
 CNE Credit
 CHES Credit
 CPE Credit

Last Name (print or type) _____ First Name _____
 Street Address or P.O. Box _____
 Apartment _____ or _____ Suite _____
 City _____ State _____ ZIP Code _____
 Phone Number _____ Fax Number _____
 E-Mail Address _____

Fill in the appropriate blocks to indicate your answers. Remember, you must answer all of the questions to receive continuing education credit!

| | |
|---|---|
| 1. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 14. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 2. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 15. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 3. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 16. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 4. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 17. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 5. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 18. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 6. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 19. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 7. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 20. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 8. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 21. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 9. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 22. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 10. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 23. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 11. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 24. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 12. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 25. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |
| 13. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] | 26. [] A [] B [] C [] D [] E [] F [] G [] H [] I [] J [] K [] L [] M [] N [] O [] P [] Q [] R [] S [] T [] U [] V [] W [] X [] Y [] Z [] |

Signature _____ Date I Completed Exam _____

22. These recommendations will improve the quality of my practice.

- A. Strongly agree.
- B. Agree.
- C. Undecided.
- D. Disagree.
- E. Strongly disagree.

23. The availability of continuing education credit influenced my decision to read this report.

- A. Strongly agree.
- B. Agree.
- C. Undecided.
- D. Disagree.
- E. Strongly disagree.

24. The *MMWR* format was conducive to learning this content.

- A. Strongly agree.
- B. Agree.
- C. Undecided.
- D. Disagree.
- E. Strongly disagree.

25. Do you feel this course was commercially biased? (*Indicate yes or no; if yes, please explain in the space provided.*)

- A. Yes.
- B. No.

26. How did you learn about the continuing education activity?

- A. Internet.
- B. Advertisement (e.g., fact sheet, *MMWR* cover, newsletter, or journal).
- C. Coworker/supervisor.
- D. Conference presentation.
- E. *MMWR* subscription.
- F. Other.

Correct answers for questions 1-10.
1. E; 2. G; 3. D; 4. E; 5. A; 6. B; 7. E; 8. C; 9. E; 10. B.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's Internet server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/publications/mmwr>. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to www.mmwrq@cdc.gov.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

FDA Approval of an Extended Period for Administering VariZIG for Postexposure Prophylaxis of Varicella

VariZIG (Cangene Corporation, Winnipeg, Canada) is the only varicella zoster immune globulin preparation available in the United States for postexposure prophylaxis of varicella in persons at high risk for severe disease who lack evidence of immunity to varicella and are ineligible for varicella vaccine. VariZIG is available in the United States through an investigational new drug (IND) application expanded access protocol (1). VariZIG is a purified immune globulin preparation made from human plasma containing high levels of anti-varicella zoster virus antibodies (immunoglobulin G). In May 2011, the Food and Drug Administration (FDA) approved an extended period for administering VariZIG. The period after exposure to varicella zoster virus during which a patient may receive VariZIG, which had been 96 hours (4 days), is now 10 days (1). VariZIG should be administered as soon as possible after exposure (1).

Limited data suggest that the incidence of varicella is comparable among persons who receive varicella zoster immune globulin within 4 days of exposure and those who receive it more than 4 days (up to 10 days) after exposure and attenuation of disease might be achieved with administration of varicella zoster immune globulin up to 10 days after exposure (2–5). One study indicated an increase in varicella incidence with increasing time between exposure and administration of the immune globulin, but disease was attenuated in all cases (6).

VariZIG can be obtained by health-care providers from the sole-authorized U.S. distributor, FFF Enterprises (Temecula, California), by calling 800-843-7477 at any time or by contacting the distributor online at <http://www.fffenterprises.com>. As with any product used under an IND protocol, patients must give informed consent before receiving the product.

Advisory Committee on Immunization Practices (ACIP) recommendations regarding indications for the use of VariZIG remain unchanged (7,8). Patients without evidence of immunity to varicella (i.e., without a health-care provider diagnosis or verification of a history of varicella or herpes zoster, documentation of vaccination, or laboratory evidence of immunity or confirmation of disease) who are at high risk for severe disease and complications, who have been exposed to varicella or herpes zoster, and are ineligible for varicella vaccine, are eligible to receive VariZIG (7). Patient groups recommended by ACIP to receive VariZIG include the following:

- Immunocompromised patients.
- Neonates whose mothers have signs and symptoms of varicella around the time of delivery (i.e., 5 days before to 2 days after).
- Premature infants born at ≥ 28 weeks of gestation who are exposed during the neonatal period and whose mothers do not have evidence of immunity.
- Premature infants born at < 28 weeks of gestation or who weigh $\leq 1,000$ g at birth and were exposed during the neonatal period, regardless of their mothers' evidence of immunity status.
- Pregnant women.

VariZIG should be administered intramuscularly as directed by the manufacturer. Additional information on the process for obtaining VariZIG under the IND protocol, use of antiviral therapy if varicella occurs after administration of VariZIG, and the interval between administration of VariZIG and varicella vaccine once the patient becomes eligible is available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a5.htm> (8).

References

1. Food and Drug Administration. Varicella zoster immune globulin (VZIG) anticipated short supply and alternate product availability under an investigational new drug application expanded access protocol. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2006. Available at <http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm176029.htm>. Accessed March 28, 2012.
2. Evans EB, Pollock TM, Craddock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. *Lancet* 1980;315:354–6.
3. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. *Rev Med Microbiol* 1993;4:222–30.
4. Enders G, Miller E. Varicella and herpes zoster in pregnancy and the newborn. In: Arvin A, Gershon A, eds. *Varicella-zoster virus: virology and clinical management*. Cambridge, UK: Cambridge University Press; 2000.
5. Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. *J Clin Pharmacol* 2002;42:267–74.
6. Winsnes R. Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients. *Acta Paediatr Scand* 1978;67:77–82.
7. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2007;56(No. RR-4).
8. CDC. A new product (VariZIG™) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. *MMWR* 2006;55:209–10.